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Abstract 
Heart disease is the biggest killer world-wide, causing a quarter of all deaths. 
During the past two decades, it has also risen above infectious diseases as the 
leading cause of years of life lost. Heart failure, characterized by weak pump 
function of the heart, and disturbances in heart rhythm (arrhythmias) are com-
mon and interrelated mechanisms underlying cardiac mortality. 
 
Intracellular calcium ions are crucial to contraction and relaxation of the heart 
muscle, as well as to control of its rhythm. How calcium is handled and regu-
lated is thus essential to normal cardiac function, and disturbances in these 
processes can have catastrophic consequences. Understanding the mechanisms 
of these disturbances is important for improving disease prevention, diagnosis, 
and management. The studies in this thesis focus on two conditions where 
cardiac calcium handling is impaired. Studies I – III examine the mechanisms 
of a genetic arrhythmia disease named catecholaminergic polymorphic ven-
tricular tachycardia (CPVT), which is characterized by stress-induced ven-
tricular tachycardia in a structurally normal heart. Study IV investigates cardi-
ac function in a model of another genetic disease, autosomal dominant poly-
cystic kidney disease (ADPKD). This systemic disease mainly affects the kid-
neys, and the mechanisms of the concomitant decline in cardiac function have 
thus far remained underinvestigated. 
 
We evaluated clinical data on cardiac function of CPVT patients, including 
24h electrocardiograms, intracardiac monophasic action potential recordings, 
and exercise stress tests. We used cell models to study the underlying disease 
mechanisms in detail. During conditions of stress, CPVT cells showed in-
creased spontaneous and irregular release of calcium from within the intracel-
lular stores through the cardiac ryanodine receptors. These receptors, which 
function as intracellular calcium release channels, harbor the disease-causing 
mutation. The spontaneous release of calcium led to changes in the membrane 
potential of the cells, manifested as afterdepolarizations during the resting 
phase of the cardiac cycle. These afterdepolarizations were reproduced in the 
clinical monophasic action potential recordings of CPVT patients, and were 
shown to trigger arrhythmias in these patients. Changes in intracellular calci-
um alter the membrane potential, and these changes are reflected on the elec-
trocardiogram. Thus, irregularities that might correspond to those observed in 
the cell model were then investigated in 24h electrocardiograms of CPVT pa-
tients. Increased irregularity of cardiac repolarization was found in the CPVT 
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patients. Such irregularity was greater in the electrocardiograms of CPVT pa-
tients with a history of more severe arrhythmic events. Additionally, we found 
slowed depolarization in response to stress in CPVT cells and patients, sug-
gesting reduced conduction velocity might contribute to an arrhythmic sub-
strate in these patients.  
 
Cardiac function in ADPKD caused by mutations in polycystin-2, another 
intracellular calcium channel, was investigated in a zebrafish model lacking 
expression of the polycystin-2 protein. The zebrafish lacking polycystin-2 
showed signs of heart failure, including reduced cardiac output, edema, and 
arrhythmias. Hearts, which were then examined in more detail ex vivo, showed 
impaired cycling of intracellular calcium, which is likely to underlie the cardi-
ac dysfunction observed in vivo. The association of ADPKD with idiopathic 
dilated cardiomyopathy (IDCM) was examined using the Mayo ADPKD Mu-
tation Database, which contains data on genotyped ADPKD patients. Exami-
nation of the ADPKD Database showed IDCM to be very common among 
ADPKD patients. IDCM was most prevalent in patients with mutations in 
polycystin-2, suggesting impaired calcium cycling as a potential pathomecha-
nism. 
 
Studies I-III shed new light on mechanisms of arrhythmias in CPVT and relat-
ed conditions, opening the way for future studies on arrhythmia risk and thera-
peutic evaluation. Furthermore, the results encourage pursuing the novel stem 
cell models for studying pathomechanisms and therapeutics. Study IV showed 
an association between ADPKD and IDCM. The zebrafish model suggested 
impaired calcium cycling as an underlying mechanism, highlighting the use-
fulness of zebrafish as a model in cardiac research.  
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Tiivistelmä – Finnish summary 
Sydänsairaudet ovat maailmanlaajuisesti yleisin kuolinsyy, aiheuttaen 
neljänneksen kuolemista. Kahden viime vuosikymmenen aikana ne ovat 
ohittaneet tartuntataudit suurimpana menetyttyjen elinvuosien aiheuttajana. 
Sydämen vajaatoiminta ja rytmihäiriöt ovat sydänkuolleisuuden taustalla 
olevia yleisiä ja toisiinsa liittyviä mekanismeja. 
 
Solunsisäiset kalsiumionit ovat elintärkeitä sekä sydämen supistuvuuden ja 
relaksaation, että sen rytmin säätelyn kannalta. Kalsiumin tiukka säätely on 
siten sydämen normaalin toiminnan edellytys, ja tämän säätelyn häiriöillä voi 
olla vakavia seuraamuksia. Näiden häiriöiden mekanismien ymmärtäminen on 
tärkeää sairauksien ehkäisyn, diagnostiikan ja hoidon kannalta. Tämän 
väitöskirjan osatyöt paneutuvat kahteen sairauteen, joissa sydämen 
solunsisäisen kalsiumin säätely on häiriintynyt. Osatyöt I – III tutkivat 
katekoliaminergisen monimuotoisen kammiotiheälyöntisyyden (CPVT) 
mekanismeja. Tämä perinnöllinen rytmihäiriösairaus aiheuttaa henkeä 
uhkaavaakin kammiotiheälyöntisyyttä stressin yhteydessä rakenteellisesti 
terveessä sydämessä. Osatyössä IV tutkitaan sydämen toimintaa liittyen 
autosomissa vallitsevasti periytyväään munuaisten monirakkulatautiin 
(ADPKD). Tämä perinnöllinen systeeminen sairaus vaikuttaa oleellisesti 
munuaisiin, mutta samanaikainen sydämen toiminnan heikkeneminen on 
jäänyt vähemmälle huomiolle. 
 
Arvioimme sydämen toimintaa CPVT-potilailla käyttäen menetelminä 
sydänsähkökäyrän pitkäaikaisnauhoitusta, sydämen rasituskoetta ja 
elektrofysiologista tutkimusta, johon sisältyi oikean kammion 
aktiopotentiaalimittaus. Lisäksi käytimme solumalleja mekanismien 
yksityiskohtaiseen selvittämiseen. CPVT:n taustalla ovat mutaatiot sydämen 
ryanodiinireseptorissa, joka on kalsiumin säätelyssä oleellinen solunsisäinen 
kalsiumkanava. Stressin yhteydessä CPVT-soluissa esiintyi lisääntynyttä 
spontaania ja epäsäännöllistä kalsiumin vapautumista solunsisäisistä 
varastoista mutatoituneiden ryanodiinireseptorien läpi. Tämä johti solukalvon 
jännitteen muutoksiin, jotka havaittiin sydämen lepovaiheen aikana ilmenevinä 
jälkidepolarisaatioina. Vastaavia jälkidepolarisaatioita havaittiin myös CPVT-
potilaiden aktiopotentiaalimittauksissa, missä ne ajoittain laukaisivat 
kammiolisälyöntejä. Solunsisäisen kalsiumpitoisuuden muutokset vaikuttavat 
solukalvon jännitteeseen, mikä taas heijastuu sydänsähkökäyrään. Tämän 
vuoksi solumallissa todettua kalsiumpitoisuuden vaihtelua vastaavia 
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muutoksia tutkittiin CPVT-potilaiden sydänsähkökäyrissä. Vastaavasti, myös 
sydämen repolarisaation vaihtelu oli lisääntynyt CPVT-potilailla. Tämä 
vaihtelu oli suurempaa niiden CPVT-potilaiden sydänsähkökäyrissä, joilla oli 
aiemmin todettuja vakavia rytmihäiriötapahtumia. Tämän lisäksi löysimme 
CPVT-soluilla ja -potilailla stressin yhteydessä hidastuvaa depolarisaatiota, 
viitaten hidastuneen sähköisen johtumisen mahdolliseen osuuteen 
rythmihäiriölttiutta lisäävänä tekijänä näillä potilailla. 
 
Tutkimme sydämen toimintaa polykystiini-2:n mutaatioista aiheutuvassa 
ADPKD-mallissa. Käytetyltä seeprakalamallilta puuttuu polykysteiini-2-
proteiini, joka normaalisti muodostaa solunsisäisen kalsiumkanavan. 
ADPKD:n yhteyttä tuntemattomasta syystä johtuvaan laajentavaan 
sydänlihassairauteen (IDCM) tarkasteltiin Mayo-klinikan ADPKD 
tietokannasta, joka sisältää tietoa genotyypatuista ADPKD-potilaista. 
Seeprakalamallissa todettiin sydämen vajaatoimintaan viittaavina löydöksinä 
alentunut sydämen minuuttitilavuus, turvotusta ja rytmihäiriöitä. Kalojen 
sydämiä tutkittiin tarkemmin kuvantamalla solunsisäistä kalsiumia, jonka 
säätelyn havaittiin olevan heikentynyttä ADPKD-kaloilla sopien havaitun 
sydämen vajaatoiminnan syyksi. Mayo-klinikan tietokannassa IDCM oli 
yleinen diagnoosi ADPKD-potilaiden keskuudessa. Vallitsevuus etenkin 
polykystiini-2-mutaatioita kantavien ADPKD-potilaiden keskuudessa oli 
yleistä, viitaten heikentyneeseen kalsiumin säätelyyn mahdollisena 
tautimekanismina. 
 
Osatyöt I – III tuovat uutta tietoa CPVT:n ja senkaltaisten tautitilojen 
yhteydessä esiintyvien rytmihäiriöiden mekanismeista, avaten samalla tien 
tuleville rytmihäiriöriskiin ja hoidon tehon arviointiin liittyville tutkimuksille. 
Lisäksi tulokset kannustavat jatkamaan uusien solumallien käyttöä 
tautimekanismeihin ja hoitoihin liittyvissä tutkimuksissa. Osatyö IV:ssä 
havaittiin yhteys ADPKD:n ja IDCM:n välillä. Tutkimukset seeprakalamallilla 
viittaavat heikentyneeseen solunsisäisen kalsiumin säätelyyn taustalla olevana 
mekanismina, samalla alleviivaten seeprakalamallin käyttökelpoisuutta 
sydäntutkimuksessa. 
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VF ventricular fibrillation 
VT              ventricular tachycardia 
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Introduction 
Globally, heart disease is the number one cause of mortality and years of life 
lost. It is not just the elderly who are directly affected: in women aged 15 – 49, 
cardiovascular disease is the third biggest killer after HIV/AIDS and a group 
of other non-communicable diseases. In men aged 15 – 49, it is the biggest 
killer (Lozano et al. 2012). Besides being the biggest single killer, ischemic 
heart disease often leads to declined cardiac function and heart failure. In pa-
tients with heart failure, loss of adequate pump function and sudden cardiac 
death (SCD) due mainly to ventricular arrhythmias are equally common causes 
of mortality (Tomaselli et al. 1994). The hard work of scientists over the last 
decades has tremendously improved our understanding of the mechanisms 
behind failing cardiac function and lethal arrhythmias. Yet, much remains 
incompletely understood.  
 
A common thread linking impaired pump function of the heart to lethal ar-
rhythmias has started to emerge: abnormal intracellular Ca2+ handling (Laurita 
et al. 2008b, Aistrup et al. 2011). Ca2+ is essential for muscle contraction. 
However, when it gets mishandled, it is not just the contraction and relaxation 
that are affected. Ca2+ can also trigger, sustain, and perpetuate arrhythmias, 
with possibly disastruous consequences. 
 
In this thesis, I present the results of our investigations on the mechanistic role 
of intracellular Ca2+ cycling in pathology linked to arrhythmias in catechola-
minergic polymorphic ventricular tachycardia (CPVT) and cardiac dysfunction 
in autosomal dominant polycystic kidney disease (ADPKD). Both diseases are 
inherited conditions that in addition to investigating disease-specific 
pathomechanisms, offer the possibility of gaining a better understanding of 
disease processes linked to abnormal intracellular Ca2+ handling more broadly.  
 
Studies I – III focus on the mechanisms of arrhythmias in CPVT. Clinical data 
including monophasic action potential (MAP) recordings, electrocardiograms 
(ECG), and exercise stress tests, are combined with investigation of the disease 
at the molecular and cellular levels by using traditional and modern cell mod-
els. The arrhythmias in CPVT resemble those seen in patients with heart fail-
ure. Therefore the implications of these findings touch a far broader population 
than those suffering from this fairly rare genetic condition.  
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Study IV examines cardic function in ADPKD using a zebrafish model and 
clinical data on ADPKD patients. Based on detailed investigation of in vivo 
and ex vivo cardiac function in the model organism, clinical data on ADPKD 
patients are examined for the prevalence of heart failure. ADPKD is the most 
common inherited kidney disease and is associated with substantial cardiovas-
cular morbidity and mortality. The mechanisms of cardiac dysfunction in these 
patients remain underinvestigated and poorly understood. 
 
In all four studies, basic research methods are combined with clinical patient 
data in an attempt to bridge the gap between basic research and the clinic, 
helping to translate insights gained in the lab to benefit the patients. Before 
presenting and discussing our findings, I review the essential concepts and 
take a look at where we currently stand in our understanding of the role of Ca2+ 
in arrhythmias and heart failure. 
17 
 
Review of literature
ELECTRICAL ACTIVITY OF THE HEART 
1.1   The cardiac action potential and its conduction 
 
The heart pumps blood around the circulatory system, hence facilitating the 
delivery of oxygen and nutrients to target tissues all over the body and the 
removal of waste products from them. To achieve this, the heart contracts and 
relaxes rhythmically. The rhythmic action is based on the generation of action 
potentials (AP), which are the fundamental manifestations of electrical activity 
in the heart. Action potentials are short cyclic events resulting from the trans-
fer of various ions between the outside and inside of the cells through special-
ized channels on the cellular plasma membrane of the cardiomyocytes, known 
as the sarcolemma (Nerbonne et al. 2005). The movement of ions results in 
changes of membrane potential that are in the order of 100 millivolts (mV). 
Under normal conditions, APs are generated in specialized pacemaker cells of 
the sinoatrial node, located in the right atrium of the heart. Thus the
 
 
Figure 1. A simplified schematic of the heart’s electrical conduction system (yellow) 
and typical AP characteristics of different cell types. SAN = sinoatrial node, AVN = 
atrioventricular node, RA = right atrium, LA = left atrium, RV = right ventricle, LV = 
left ventricle. 
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expression: “sinus rhythm”. The APs reach neighboring cells by sarcolemmal 
channels called gap junctions, which permit the flow of current, enabling 
propagation (Rohr 2004). The APs are conducted through the atria into the 
atrioventricular (AV) node, located between the atria and the ventricles. From 
the AV node, the only conductive route between the atria and the ventricles 
under normal conditions, the APs travel along Purkinje fibers to finally 
achieve synchronized excitation of the ventricular myocardium. The Purkinje 
cells are modified cardiomyocytes, capable of rapid conduction. Due to the 
differential expression of ion channels, the shape and duration of the AP varies 
greatly based on the type of heart cell in question, as demonstrated in figure 1. 
 
1.2   Sarcolemmal ion channels and currents in the cardiomyocyte 
 
Here I shall concentrate on the ventricular AP, as it is most essential to this 
study. The AP is generally divided into four phases (figure 2). Each phase is 
characterized by a distinct combination of tightly controlled ion currents 
(Amin et al. 2010). These ion currents result from the opening and closing 
(known as gating) of sarcolemmal ion channels (Grant 2009). The gating of 
relevant cardiac ion channels is dependent on the membrane potential. As the 
membrane potential reaches a certain threshold, these channels open or close. 
Closure of the channels is associated with a period of inactivation, which un-
derlies refractoriness during which the channels are unable to re-activate 
(open). The current amplitude through an ion channel is determined by its 
conductivity and by the membrane potential. Currents through ion channels in 
which the current amplitude does not increase linearly with its conductivity are 
known as rectifying currents. In such channels conductivity varies depending 
on the membrane potential. Ions tend to move down their concentration gradi-
ent. At equilibrium potential, referred to as the Nernst potential, the net current 
across the membrane is zero. The equilibrium potential of a specific ion de-
pends on its concentrations inside and outside the cell, as well as on the tem-
perature. During the resting phase of the ventricular cardiomyocyte (phase 4), 
the membrane potential is typically -90 mV, with the inside of the cell being 
negatively charged. The negative resting potential is largely due to the inward-
ly rectifying potassium current (IK1), resulting from K
+ ions flowing out of the 
cell, and is close to the equilibrium potential for K+. When an AP reaches the 
cell, Na+ and some Ca2+ ions flow into it from neighboring cells via gap junc-
tions, increasing the membrane potential, hence partly depolarizing the cell. 
When the cell reaches a threshold potential of about -70 mV, the fast, voltage-
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gated Na+ channels open resulting in an inward sodium current (INa) (phase 0). 
At the same time, the inwardly rectifying K+ channels close, helping to move 
the potential from the negative K+ equilibrium potential towards the positive 
Na+ equilibrium potential. This causes the voltage-gated Na+ channels to close 
and transient K+ channels to briefly open, producing a hyperpolarizing notch to 
the AP due to fast and slow transient outward K+ currents (Ito,f and Ito,s)(phase 
1). Phase 2 is referred to as the plateau phase, resulting from a balance be-
tween inward L-type Ca2+ current (ICa,L) through the voltage-gated, L-type 
calcium channels (LTCC) that open at -40 mV, and the outward K+ currents 
through the slow and rapid delayed rectifying K+ channels (IKs and IKr). The 
long plateau phase is distinctive for the ventricular AP and contributes to phys-
iologically appropriate sustained muscle contraction. Phase 3 of the AP is 
characterized by rapid repolarization. LTCCs close, while the slow delayed 
rectifying K+ channels remain open. As repolarization progresses, more rapid 
delayed rectifying K+ channels open, and now also the inwardly rectifying K+ 
channels open, produc-
ing IK1. At -85 mV, the 
delayed rectifying K+ 
channels close, but the 
IK1 continues passing 
K+ ions out of the cell, 
contributing to the rest-
ing membrane potential 
during phase 4 of the 
AP.  
 
 
 
Figure 2. AP shape in an 
adult human ventricular 
cardiomyo-cyte, showing 
its four phases and essen-
tial underlying ionic cur-
rents. Downward currents 
indicate depolarizing 
currents and upward cur-
rents repolarizing ones. 
Modified from (Nerbonne 
et al. 2005). 
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The resting membrane potential is also maintained by the Na+/K+ pump, which 
in an energy consuming process actively removes three Na+ ions from the cell 
in exchange for every two K+ ions entering the cell, also helping to maintain 
the concentrations of these ions. Additionally, the sodium-calcium exchanger 
current (INCX) contributes to the AP in potentially important ways, as is dis-
cussed below (Bers 2002). 
 
 
FROM ELECTRICAL EXCITATION TO 
MECHANICAL CONTRACTION 
1.3   Excitation-contraction coupling 
The process of translating the electrical excitation in the form of depolarizing 
current of the AP into muscle contraction of the cardiac chambers is referred to 
as excitation-contraction coupling. To understand how it works, we must fol-
low and understand the movements of the crucial messenger – calcium (Bers 
2002).  
1.4   Calcium cycling – meet the key players 
Transverse tubules (T-tubules) are invaginations of the sarcolemma. They 
make up most of the sarcolemmal area and enable rapid communication be-
tween the sarcolemma and intracellular structures (ter Keurs 2012, Ferrantini 
et al. 2013). Most sarcolemmal ion channels are concentrated to the T-tubules. 
During the plateau of the AP, Ca2+ enters the cell via voltage-gated LTCCs as 
an inward Ca2+ current (ICa,L) as shown in figure 2. This entry of Ca
2+ triggers a 
much larger release of Ca2+ from the sarcoplasmic reticulum (SR) in a process 
called calcium-induced calcium release (figure 3). The SR is an intracellular 
organelle specialized in storage and cycling of Ca2+. The release of Ca2+ from 
the SR into the cytosol takes place via specialized calcium channels on the SR 
membrane, the cardiac ryanodine receptors (RyR2), which are organized into 
close physical contact with the LTCCs of the sarcolemma. The high concentra-
tion of free intracellular calcium [Ca2+]i activates the contractile apparatus. 
Cardiac calsequestrin (CASQ2) functions as a Ca2+ buffer in the SR, and tri-
adin anchors it to RyR2 (Guo et al. 1995, Zhang et al. 1997). Unphosphory-
lated FKBP12.6 (calstabin2) binds to RyR2, stabilizing its function (Marx et al. 
2000). For muscle relaxation to take place, [Ca2+]i must fall. This is achieved 
by pumping Ca2+ out of the cytosol. Most of it is pumped back into the SR by 
the SR Ca2+ ATPase (SERCA2a). SERCA2a is inhibited by unphosphorylated
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phospholamban (PLB). Ca2+ also leaves the cytosol via the sodium-calcium 
exchanger channel (NCX), one Ca2+ ion in exchange for three Na+ ions enter-
ing from the extracellular space. Additionally, minor amounts of Ca2+ are re-
moved by the sarcolemmal Ca2+ ATPase and the mitochondrial Ca2+ uniporter 
(Bers 2002). These fast cyclic increases and decreases in [Ca2+]i are known as 
Ca2+ transients. The SR membrane also harbors additional Ca2+ channels. The 
inositol 1,4,5-trisphosphate receptors (IP3R) are important in cardiac devel-
opment, signaling, and also play roles in pathophysiology (Kockskamper et al. 
2008, Signore et al. 2013). Additionally, polycystin-2 (PC2) is known to form 
a Ca2+-activated Ca2+ channel on the SR membrane (Koulen et al. 2002).  
Figure 3. Calcium cycling in the cardiomyocyte. LTCC = L-type Ca2+ channel, 
CaMKII = Ca2+/calmodulin-dependent protein kinase II, NCX = Sodium-calcium 
exchanger, C = Calstabin2 (FKBP12.6), PKA = Protein kinase A, RyR2 = Cardiac 
ryanodine receptor, CASQ2 = Cardiac calsequestrin, SERCA = Sarcoplasmic reticu-
lum Ca2+ ATPase, PLB = Phospholamban, PC2 = Polycystin-2, cAMP = Cyclic aden-
osine monophosphate, SR = Sarcoplasmic reticulum, IP3R2 = Type 2 inositol 1,4,5-
	



	-adrenergic receptor, T-tubule = Transverse tubule.
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The function of these key proteins in Ca2+ cycling is modulated by 
Ca2+/calmodulin-dependent protein kinase II (CaMKII), which phosphorylates 
RyR2, increasing Ca2+ transient magnitude and spontaneous Ca2+ release from
the SR. CaMKII also phosphorylates PLB, relieving its inhibition of SER-
CA2a and thus increasing SR Ca2+ reuptake, and LTCC, increasing ICa,L (Yuan 
et al. 1994, Maier et al. 2007). Furthermore, CaMKII modulates Na+ channels, 
K+ channels, and inositol 1,4,5-trisphosphate receptors (IP3R), which are also 
expressed on the nuclear envelope, where they colocalize with CaMKII and 
contribute to regulation of gene transcription (Bers et al. 2009). CaMKII is 
activated by a rise in [Ca2+]i, which can be due to reactive oxygen species, -
adrenergic receptor stimulation, angiotensin II, aldosterone, or hyperglycemia 
(Luo et al. 2013). 
 
Another essential regulator on cardiac Ca2+ cycling is protein kinase A (PKA). 
Circulating catecholamines epinephrine, released by the adrenal glands, and 
norepinephrine, released by the sympathetic neurons, bind and activate -
adrenergic receptors on the sarcolemma. Activation of these G protein-coupled 
receptors increases adenylyl cyclase activity, resulting in conversion of ATP to 
cyclic adenosine monophosphate (cAMP), which in turn activates PKA (Krebs 
1989, Sassone-Corsi 2012). PKA phosphorylates numerous target proteins, e.g. 
PLB, LTCC, RyR2, and likely NCX, increasing the frequency and amplitude 
of intracellular Ca2+ transients (Hain et al. 1995, Zhang et al. 2009b). This 
translates to increased heart rate and contractility, classic manifestations of the 
sympathetic fight or flight response. Importantly, PKA phosphorylatin of tro-
ponin I desensitizes troponin C to Ca2+, enabling rapid relaxation and mainte-
nance of Ca2+ cycling at rapid heart rates (Li et al. 2000) 
1.5   Calcium in heart muscle contraction and relaxation 
Elevated [Ca2+]i during systole activates the myofilaments to contract. Ca
2+ 
binds to troponin C, which goes on to move tropomyosin aside, exposing myo-
sin cross-bridges, which bind to actin. Energy in the form of ATP is then con-
verted to movement of the actin-myosin filaments relative to each other, re-
sulting in sarcomere shortening. As Ca2+ is pumped out of the cytosol, it disso-
ciates from troponin C, causing relaxation (Bers 2008). In addition to acceler-
ating [Ca2+]i decay, relaxation can be accelerated by PKA-mediated phosphor-
ylation of troponin I that accelerates unbinding of Ca2+ from troponin C, as 
mentioned above (Li et al. 2000).  
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1.6   Interplay between calcium and membrane voltage 
What makes the role of Ca2+ very interesting and important is its ability to 
modulate membrane potential (Laurita et al. 2008b). When NCX operates in 
forward mode, three Na+ ions enter the cell for every removed Ca2+ ion. This 
creates a positive inward (depolarizing) current and tends to increase AP dura-
tion (APD). NCX can also operate in reverse mode, removing three Na+ ions 
for every entered Ca2+ ion. This repolarizes the cell and tends to shorten APD. 
Therefore, increased [Ca2+]i will typically increase APD. This relationship is 
known as positive calcium to voltage coupling. However, because NCX func-
tion depends on membrane potential and Na+ in addition to Ca2+, its effect on 
APD may be difficult to predict under changing conditions. For example, dur-
ing VT the intracellular Na+ concentration may rise and lead to reverse mode 
operation of NCX, which is more rapid than inactivation of LTCC. The result-
ing inflow on Ca2+ may cause Ca2+-induced Ca2+ release, sustaining or perpet-
uating the arrhytmia.  
 
LTCC opening is regulated by negative feedback, where [Ca2+]i will inactivate 
LTCC, thus shortening APD. High [Ca2+]i also increases IKs, also shortening 
APD. This contrary relationship is called negative calcium to voltage coupling. 
The effect of [Ca2+]i on the membrane potential will therefore depend on the 
relative amount and activity of available NCX and LTCC, as well as the Na+ 
concentration and membrane potential. Additionally, high [Ca2+]i reduces INa, 
decreasing maximal upslope velocity of the AP (phase 0)(Casini et al. 2009). 
High [Ca2+]i also decreases conduction velocity of APs between cells by clos-
ing gap junctions (Peracchia 2004).  
 
 
WHEN CALCIUM GOES ROGUE – Failures of rhythm 
and pumping 
The essential pump function of the heart may be compromised by disturbances 
in its rhythm or the ability to contract and relax in a way that maintains suffi-
cient blood pressure for perfusion of target tissues. Impaired calcium handling 
is implicated in pathologies involving both rhythm and contraction/relaxation 
of the heart. 
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1.7   Mechanisms of ventricular arrhythmias – with a focus on 
calcium 
Cardiac arrhythmias can be divided into passive (e.g. AV block) and active 
ones (Antzelevitch et al. 2008, Issa et al. 2012). I will focus on active ventricu-
lar arrhythmias, which can be mechanistically divided into abnormal impulse 
formation and abnormal impulse conduction. Disorders of impulse formation 
include abnormal automaticity and triggered activity, which encompasses early 
afterdepolarizations (EAD) and delayed afterdepolarizations (DAD). Disorders 
of impulse conduction refer to block and reentry, which can be anatomical or 
functional (figure 4) (Antzelevitch et al. 2008, Issa et al. 2012).  
 
 
Figure 4. Mechanisms of cardiac arrhythmias, with an emphasis on active ventricular 
tachyarrhythmias. Ca2+ plays a key mechanistic role at multiple levels, as marked on 
the chart. The double-headed arrow signifies mechanistic similarities between EADs 
and DADs, with Ca2+ as the common denominator. 
1.7.1 Automaticity 
Cardiac cells possess an intrinsic capability to spontaneously generate APs, 
referred to as automaticity. Under normal conditions, sinoatrial node cells have 
the highest rate, and are therefore in charge of setting the rhythm, pacemaking. 
Cardiomyoctes elsewhere in the heart also have pacemaker capability, with 
decreasing intrinsic rate the further they are from the sinoatrial node. The 
pacemaking rate is controlled by the autonomic nervous system and by extra-
cellular ion concentrations, namely K+. Abnormal automaticity may arise un-
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der conditions of higher resting membrane potential, such as ischemia. The 
pacemaking rate is proportional to the resting membrane potential. Hence ab-
normal automaticity results in high rates of pacemaking. Release of Ca2+ from 
the SR may be mechanistically important in abnormal automaticity, and lead 
to depolarizing currents through activation of NCX, similar to the mechanism 
of DADs. Abnormal automaticity is not likely responsible for the majority of 
ventricular tachyarrhythmias, but it can be an initiating factor to arrhythmias 
sustained by reentrant mechanisms. In practise, it is difficult to mechanistically 
distinguish abnormal automaticity from localized reentrant mechanisms, as 
well as from triggered activity (Antzelevitch et al. 2008). 
1.7.2 Early afterdepolarizations 
EADs are depolarizing oscillations in membrane potential that take place dur-
ing repolarization, at phase 2 or 3 of the AP (figure 5). Prolongation of APD 
predisposes to EADs. For example, in patients with long QT syndrome, EAD-
induced triggered activity is considered the factor that initiates torsades de 
pointes, a potentially lethal form of ventricular tachycardia (VT). Additionally, 
multiple other factors predispose to EAD, among them electrolyte abnormali-
ties, hypoxia, catecholamines, and heart failure. At the cellular level, EADs are 
associated with reduced repolarizing K+ currents, increased Ca2+ current, in-
creased NCX activity, and increased late Na+ current (Antzelevitch et al. 2008). 
It is well established that the upslope of the EAD is due to ICa,L, making LTCC 
recovery from inactiva-
tion followed by its acti-
vation a prerequisite for 
EAD-induced triggered 
activity (January et al. 
1992).  
 
Figure 5. EADs occur be-
fore the end of repolariza-
tion. They are preceded by 
conditioning phases, transi-
ent delays in repolarization 
due to inward currents. 
DADs occur after the com-
pletion of repolarization. 
Both EADs and DADs will 
trigger an AP if they reach 
threshold voltage. This is 
called triggered activity. 
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Less clear are the mechanisms accounting for the so called “conditioning 
phase”, which is a transient delay of repolarization deemed necessary for EAD 
formation. An emerging view centers on [Ca2+]i as the key contributor to the 
conditioning phase of EADs and highlights the similarity to DADs (Volders et 
al. 2000). Intracellular Ca2+ overload or spontaneous SR Ca2+ release activates 
NCX, which is the source of the depolarizing current that leads to LTCC acti-
vation (Volders et al. 1997, Choi et al. 2002). Additionally, phase 3 EADs that 
occur below the threshold potential for LTCC activation (< ~ -35mV), appear 
NCX-mediated and are thus mechanistically similar to DADs (Patterson et al. 
1990, Xu et al. 1996, Spencer et al. 2003). Recently, late phase 3 EADs have 
been described associated with shortened APD following the end of rapid acti-
vation (e.g. termination of atrial fibrillation). These late phase 3 EADs are 
distinguished by the associated normal SR Ca2+ release, as opposed to sponta-
neous release in other forms of afterdepolarizations (Burashnikov et al. 2006).  
1.7.3 Delayed afterdepolarizations 
DADs are depolarizing oscillations in membrane potential that follow an AP 
and occur after completion of repolarization, in phase 4 (figure 5). If depolari-
zation reaches a threshold, it will induce an AP. This is called triggered activi-
ty. DADs occur under conditions of high [Ca2+]i, such as during high plasma 
concentrations of digitalis or catecholamines. As discussed above, catechola-
mines raise [Ca2+]i by PKA-mediated phosphorylation of target proteins. NCX 
pumps one Ca2+ ion out of the cell in exchange for three Na+ ions, resulting in 
a positive inward (depolarizing) current, manifested as a DAD. As RyR2 is the 
channel responsible for the large release of Ca2+ from the SR, regulation of 
RyR2 function is crucial to development of DADs. DADs and DAD-induced 
triggered activity are thus mechanistically implicated in multiple forms of VT. 
DAD-induced triggered activity is observed under conditions of normal RyR2 
function (digitalis toxicity), as well as under conditions of abnormal RyR2 
function, such as in patients with heart failure or mutations in RyR2, as will be 
discussed below (Laurita et al. 2008b).  
1.7.4 Block and reentry 
Conduction block, or wavebreak, is a prerequisite for reentry (Antzelevitch et 
al. 2008). Block can be caused by anatomical or functional heterogeneities, as 
is the case with reentry itself. In reentry, the electrical impulse persists in the 
cardiac tissue beyond the tissue’s refractory period, thus reexciting the same 
tissue. A classical example of anatomical reentry is the formation of a reen-
trant loop between the atria and ventricles using the AV node and an accessory 
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conduction pathway between the atria and ventricles, as happens in Wolff-
Parkinson-White syndrome (Al-Khatib et al. 1999). Other examples of ana-
tomical factors include scar tissue following a myocardial infarct, or fibrosis in 
a hypertrophied heart. Such fibrosis may arise due to apoptosis and necrosis of 
cardiomyocytes in response to elevation of [Ca2+]i, demonstrating how dysreg-
ulated Ca2+ contributes even to an anatomical substrate for arrhythmias 
(Demaurex et al. 2003, Chen et al. 2005, Nakayama et al. 2007, Dorn 2009). 
Functional block typically occurs when the propagating impulse encounters a 
refractory region that has not yet recovered from previous excitation. This is 
underlied by spatial heterogeinities of the refractory period. A newer concept 
is the restitution hypothesis, which predicts block to occur when the slope of 
the APD restitution curve is greater than one. This is determined by plotting 
the APD against the preceding diastolic interval (Taggart et al. 2008). More 
recently, also restitution of conduction velocity has been shown to influence 
conduction block (Weiss et al. 2005). However, the most recent evidence 
points toward an essential role for Ca2+ cycling heterogeneities as the underly-
ing cause behind dyssynchrony and alterations in membrane potential leading 
to conduction block and reentry (Chudin et al. 1999, Omichi et al. 2004). This 
type of alternating pattern of the AP has been associated with wavebreak and 
ventricular fibrillation (VF) (Pastore et al. 1999). Alternans is discussed in 
more detail below.  
 
In addition to conduction block, prerequisites for reentry include a vulnerable 
substrate with heterogeinities in conduction and refractoriness, and a trigger in 
the form of an EAD, DAD, abnormal automaticity, or reflective or type 2 reen-
trant excitation (Antzelevitch et al. 2008). A vulnerable substrate may com-
prise anatomic or functional heterogeneities, highlighted by reduced conduc-
tion velocity and shortened APD. In the case of a trigger at a vulnerable time 
and place, this shortened wavelength (= conduction velocity x refractory peri-
od) allows the excitation to reenter a part of tissue that has regained excitabil-
ity, leading to circuitous propagation of the impulse. Models for functional 
reentry include the leading circle, figure of eight, and spiral wave (rotor). Spi-
ral wave formation is considered important in the degeneration of monomor-
phic VT to polymorphic VT and VF (Davidenko 1993, Samie et al. 2001). 
Aberrant Ca2+ cycling is implicated in this process. Elevated [Ca2+]i and spatial 
heterogeinities in [Ca2+]i translate via the NCX to heterogeinities of APD. In 
regions of prolonged APD, encountering the incoming spiral wave results in 
decreased conduction velocity, block, and wavebreak (Chudin et al. 1999).  
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1.7.5 Alternans 
Calcium alternans is defined as the beat-to-beat alternation of intracellular 
calcium transient magnitude (large-small-large-small etc.) and corresponds to 
APD alternans (short-long-short-long etc). For long, it was thought that Ca2+ 
alternans was secondary to APD alternans (Koller et al. 1998, Watanabe et al. 
2001). However, recently Ca2+ has emerged as the key player behind ar-
rhythmogenic cardiac alternans (Pruvot et al. 2004, Laurita et al. 2008b, 
Narayan et al. 2008, Bayer et al. 2010, Gaeta et al. 2012). Alternans can occur 
at a subcellular, cellular, and tissue level. When tissue level alternans is in 
phase, meaning that adjacent regions of the heart show similar APD at a given 
time, it is referred to as concordant alternans. When alternans falls out of phase 
between adjacent regions, long APD in one region and short APD in another, it 
is called discordant alternans (figure 6).  
 
It is this discordant alternans that is thought to be arrhythmogenic by increas-
ing spatial heterogeneities of APD and thus predisposing to conduction block 
and reentry (figure 7) (Wilson et al. 2007).  
 
Several factors may influence the development of Ca2+ alternans, which devel-
ops when one or more key components of the Ca2+ cycling machinery fails to 
maintain a sufficient rate of Ca2+ cycling. Alternans may be due to impaired 
SR Ca2+ release. There are con-
troversial findings about wheth-
er or not this is associated with 
alternans of SR Ca2+ content 
(Shiferaw et al. 2003, Diaz et al. 
2004, Picht et al. 2006).  
 
Figure 6. Drawing of simultaneous 
intracellular Ca2+ transients and 
APs demonstrating concordant and 
discordant cardiac alternans. Num-
bers 1 and 2 refer to adjacent re-
gions of cardiac tissue. In concord-
ant alternans, the adjacent regions 
oscillate in phase, whereas in dis-
cordant alternans the adjacent re-
gions are out of phase. This type of 
spatially discordant alternans pre-
disposes to block and reentry. 
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Some findings implicate slow recovery from inactivation of RyR2, such that 
full recovery is reached only after every other beat, resulting in an alternating 
magnitude of Ca2+ release (Picht et al. 2006, Restrepo et al. 2008). Overall, 
most evidence associates Ca2+ alternans with decreased RyR2 open probability 
and increased refractoriness of the channels (Diaz et al. 2002, Xie et al. 2008a, 
Nivala et al. 2012). However, others have found increased RyR2 open proba-
bility to produce Ca2+ alternans (Lehnart et al. 2006). Findings in heart failure 
implicate impaired SR 
Ca2+ reuptake by SER-
CA2a in development 
of Ca2+ alternans 
(Pieske et al. 1995). 
 
 
Figure 7. Spontaneous 
SR Ca2+ release in region 
1 of the ventricle results 
in an EAD that induces an 
AP, which is the trigger 
initiating reentry. A vul-
nerable substrate is creat-
ed by spatially discordant 
APD alternans between 
adjacent ventricular re-
gions 1 and 2. The trigger 
in region 1 occurs at a 
vulnerable time when 
region 2 is still refractory. 
This leads to conduction 
block and initates a reen-
trant arrhythmia. Vm = 
membrane potential. 
 
1.8   Calcium in heart failure 
Globally, heart disease is the number one cause of mortality and years of life 
lost (Lozano et al. 2012). Heart failure occurs when the heart fails to suffi-
ciently perform its function of pumping blood around the circulatory system to 
meet the needs of the body. It is often caused by ischemic heart disease, high 
blood pressure, valvular disease, or cardiomyopathy (McMurray et al. 2005). 
Almost half of heart failure patients suffer SCD mainly due to ventricular 
tachyarrhythmias, putting SCD on par with failure of pump function as a cause 
of mortality in heart failure (Cohn et al. 1991, Tomaselli et al. 1994). In the 
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past decades, the essential role of impaired calcium handling has been recog-
nized as a key factor behind both weakened cardiac pump function and ar-
rhythmias in the failing heart (Gwathmey et al. 1987, Beuckelmann et al. 1992, 
Hasenfuss et al. 2002). 
1.8.1 Arrhythmias and contractile dysfunction 
In the acutely failing heart sympathetic activation is an adaptive response 
meant to maintain sufficient perfusion of target tissues. However, prolonged 
sympathetic activation turns maladaptive and contributes to progression of 
heart failure. High plasma norepinephrine levels are a strong marker of poor 
prognosis (Cohn et al. 1984). As discussed above, sympathetic activation leads 
to high [Ca2+]i, promoting arrhythmias in multiple ways (figure 8). In heart 
failure, the expression and activity of multiple Ca2+ cycling proteins is altered 
(Hasenfuss et al. 2002, Del Monte et al. 2008). The levels of LTCC are essen-
tially unchanged, but their coupling with RyR2 in the junctional SR may be 
defective. This may be due to loss of organized T-tubule structure resulting in 
dyssycronous Ca2+ release and impaired contractility (Song et al. 2006, 
Wagner et al. 2012). Many studies have found decreased RyR2 expression 
levels in failing hearts, but also contradictory findings exist. 
 
Figure 8. Mechanisms by which high [Ca2+]i promotes arrhythmias in heart failure. 
Modified from (Aistrup et al. 2011).  
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Also the findings on altered RyR2 activity remain controversial. RyR2 is 
chronically hyperphosphorylated in the failing heart. Under normal conditions, 
the accessory protein calstabin2 is bound to RyR2, stabilizing the channel. 
This interaction is modulated by PKA-mediated phosphorylation of RyR2, 
leading to dissociation of calstabin2 (Marx et al. 2000). The effects of this 
include an increase in RyR2 Ca2+ sensitivity and channel activity, as well as 
RyR2 uncoupling and dyssynchronized channel function. The resulting dias-
tolic spontaneous Ca2+ release may induce triggered arrhythmias and impair 
contractility/relaxation. However, the role of RyR2 phosphorylation and 
calstabin2 dissociation remain controversial, and some evidence points to an 
exacerbating effect of constitutive dephosphrorylation, not phosphorylation, of 
RyR2 on SR Ca2+ leak (Bers et al. 2003, Liu et al. 2014). Decreased expres-
sion of SERCA2a is a consistent finding in heart failure and correlates with 
myocardial function (Hasenfuss et al. 1994, Hasenfuss et al. 2002). Further-
more, inhibition of SERCA2a function by PLB is stronger in failing hearts 
(Frank et al. 2000). NCX expression levels are increased in heart failure, pos-
sibly to compensate for decreased SERCA2a activity, and correlate with dias-
tolic cardiac function (Hasenfuss et al. 1999). The downside of improved dias-
tolic function is an increase in the incidence of INCX-mediated triggered ar-
rhythmias (Schillinger et al. 2002). Additionally, as the NCX-LTCC balance 
shifts towards Ca2+ extrusion, the SR Ca2+ load tends to decrease, resulting in 
smaller Ca2+ transients and decreased force of contraction, a hallmark of the 
failing heart. As with dyssynchronous Ca2+ release and impaired contraction, 
Ca2+ reuptake dyssynchrony may contribute to impaired relaxation in failing 
hearts (Hohendanner et al. 2013). 
 
Mitochondrial Ca2+ is an important regulator of cell metabolism and survival. 
Mitochondrial Ca2+ overload in heart failure leads to increased production of 
reactive oxygen species, decreased production of energy, and cardiomyocyte 
apoptosis (Luo et al. 2013). CaMKII regulates this process, as well as many 
proteins involved in Ca2+ cycling, as discussed above. Under the high [Ca2+]i 
seen in heart failure, CaMKII may become constitutively activated and pro-
mote further progression of heart failure and arrhythmias. Inhibition of 
CaMKII improves cardiac function in failing hearts (Sossalla et al. 2010). 
PKA-mediated changes in activity of Ca2+ cycling proteins are mainly due to 
chronically elevated levels of plasma catecholamines in heart failure. However, 
recent finding suggest that CaMKII-mediated regulation of SR Ca2+ release via 
phosphorylation of RyR2 may be more important than PKA-mediated phos-
phorylation, especially in the transition from cardiac hypertrophy to failure 
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(Fischer et al. 2013). CaMKII activation promotes arrhythmias; phosphoryla-
tion of LTCCs and Na+ channels promotes formation of EADs and also pre-
disposes to DADs. Phosphorylation of RyR2s increases SR Ca2+ release, pro-
moting DADs. Increased apoptosis and collagen deposition increase structural 
heterogeneity and predispose to reentrant arrhythmias (Luo et al. 2013).  
 
Many structural proteins of the cytoskeleton and myofilaments, for example 
ankyrin, titin, and dystrophin, are implicated in impaired Ca2+ cycling and 
contribute to weakened cardiac function and arrhythmias in heart failure (Luo 
et al. 2013). Overall, it is worth remembering that the development of heart 
failure is a complex process, which involves changes in expression and func-
tion of hundreds if not thousands of different genes. 
 
1.9   Catecholaminergic polymorphic ventricular tachycardia 
1.9.1 Characteristics 
CPVT is an autosomally inherited syndrome characterized by VT related to 
mental or physical stress (Laitinen et al. 2001, Priori et al. 2001). Under condi-
tions of sympathetic stimulation these patients present with premature ventric-
ular contractions (PVC), bidirectional VT, polymorphic VT, and SCD in the 
absence of structural heart disease (Swan et al. 1999) (figure 9). The resting 
ECG in these patients is normal. Although a history of syncopal events is 
common, SCD may be the first manifestation. If untreated, the mortality rate 
may be as high as 50% by 20 years of age (Leenhardt et al. 1995). Early onset 
of symptoms is associated with severity of the disease. The estimated preva-
lence of CPVT in the general population is 1 in 10 000. CPVT may account 
for some cases of unexplained sudden death in children and adolescents 
(Tester et al. 2007, van der Werf et al. 2010).  
1.9.2 Genetic background 
The genetic aspect of CPVT was observed already more than half a century 
ago in a report on sisters with polymorphic ventricular arrhythmias in the ab-
sence of structural heart disease (Berg 1960). This was followed by case re-
ports with increasing patient numbers (Reid et al. 1975, Coumel 1978, 
Leenhardt et al. 1995). Over a decade ago the CPVT phenotype was associated 
with a disease locus on chromosome 1q42-43 in two Finnish families with an 
autosomal dominant mode of inheritance (Swan et al. 1999). Soon after, the 
disease-causing gene was identified as the cardiac ryanodine receptor gene 
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(RyR2)(Laitinen et al. 2001, Priori et al. 2001). Today, well over a hundred 
different RyR2 mutations have been linked to CPVT (Medeiros-Domingo et al. 
2009). RyR2 is a large gene of 105 exons. The disease-causing mutations are 
mostly missense, i.e. amino acid changing mutations and cluster in three well 
conserved regions: the N-terminal, the central region with the calstabin2 bind-
ing domain, and the C-terminal channel forming domain. Approximately 60-
70% of patients with a clinical diagnosis of CPVT harbor identifiable muta-
tions in RyR2 (Cerrone 2004, Medeiros-Domingo et al. 2009). 
 
Around the same time as RyR2 mutations were linked to CPVT, a recessive 
form of CPVT in Bedouin families was mapped to chromosome 1p13-21, and 
soon after, disease-causing homozygous missense mutations were identified in 
CASQ2 (Lahat et al. 2001a, Lahat et al. 2001b). The CASQ2 gene contains 11 
exons. To date, over twenty recessively inherited CASQ2 mutations linked to 
CPVT have been identified (Leenhardt et al. 2012). Half of these are missense
 
Figure 9. ECG during exercise stress test in a CPVT patient. During exercise worsen-
ing ventricular arrhythmias are observed. Bidirectional VT develops after 1 minute of 
exercise with a sinus heart rate of approximately 120 beats per minute. Arrhythmias 
rapidly recede during recovery. Adapted with permission from (Liu et al. 2008). 
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mutations, and the other half are nonsense mutations, leading to truncated pro-
teins. CASQ2 mutations are found is 3-5% of CPVT patients (Ackerman et al. 
2011). 
 
A novel recessive form of CPVT discovered in an Arabic family was mapped 
to chromosome 7p14-22, but the causative gene remains unknown (Bhuiyan et 
al. 2007). Recently, yet another autosomal recessive form of CPVT was asso-
ciated with mutations in triadin in two families (Roux-Buisson et al. 2012). 
The mutations resulted in the absence of the triadin protein, and also associat-
ed with skeletal muscle weakness in one of the patients.  
1.9.3 Mechanisms 
All known CPVT-causing mutations involve proteins associated with intracel-
lular Ca2+ release. The common pathomechanism is thought to be spontaneous 
leak of Ca2+ from the SR under conditions of adrenergic stimulation, resulting 
in mainly NCX-mediated diastolic inward current, DADs, and triggered ar-
rhythmias. However, several hypotheses exist on the mechanism of the spon-
taneous Ca2+ release (Wehrens 2007, Cerrone et al. 2009). The majority of 
mechanistic studies have been performed on transgenic mice. Although these 
transgenic models of RyR2 and CASQ2 have demonstrated arrhythmogenicity, 
the observed phenotype has not always resembled the human phenotype 
(Cerrone et al. 2005, Kannankeril et al. 2006, Knollmann et al. 2006, Song et 
al. 2007, Lehnart et al. 2008).  
 
The magnitude of SR Ca2+ release depends steeply on the SR Ca2+ content 
(Bassani et al. 1995). An increase in SR Ca2+ content also increases RyR2 
open probability, and thus spontaneous Ca2+ release, which is a normal phe-
nomenon under conditions of SR Ca2+ overload. (Eisner et al. 2013). The so 
called store overload-induced Ca2+ release hypothesis states that CPVT muta-
tions lower this threshold for spontaneous Ca2+ release (Jiang et al. 2002b, 
Jiang et al. 2004, Jiang et al. 2005). Recently, a luminal Ca2+-sensing gate of 
RyR2 that controls store overload-induced Ca2+ release was identified (Chen et 
al. 2014). 
 
Interactions between different domains of the RyR2 channel are essential for 
its function. One hypothesis implicates defective interdomain interactions in 
spontaneous Ca2+ release in CPVT. Impaired interaction between the N-
terminal and central regions destabilizes the closed state of the channel, result-
ing in spontaneous Ca2+ release (Ikemoto et al. 2002). In CPVT, defective 
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interdomain interaction leads to spontaneous Ca2+ release in a mutation-
dependent manner (George et al. 2006, Suetomi et al. 2011).  
 
A third hypothesis accounts spontaneous Ca2+ release to increased sensitiza-
tion of RyR2 to cytosolic Ca2+ due to dissociation of the RyR2 stabilizing pro-
tein calstabin2 (Marx et al. 2000). According to this hypothesis, RyR2 mutant 
channels have a weakened interaction with calstabin2, and adrenergic stimula-
tion via PKA-mediated phosphorylation of RyR2 further impairs this interac-
tion, causing dissociation of calstabin2, which leads to increased RyR2 open 
probability and spontaneous Ca2+ release. The benzothiazepine derivatives 
K201 (JTV519) and its follower S107 restore the impaired RyR2-calstabin2 
interaction and rescue the arrhythmogenic CPVT phenotype in mice (Wehrens 
et al. 2004, Lehnart et al. 2008). However, this hypothesis remains controver-
sial, because other groups have been unable to repeat results regarding the 
RyR2-calstabin2 interaction (George et al. 2003, Jiang et al. 2005) and the 
antiarrhythmic effects of K201 (Liu et al. 2006), as well as the dependency of 
antiarrhythmic effects of K201 on the RyR2-calstabin2 interaction (Hunt et al. 
2007). The antiarrhythmic effects of these experimental drugs may be muta-
tion dependent, or have targets other than stabilization of the RyR2-calstabin2 
interaction. To make the mechanistic soup of SR Ca2+ leak even more complex, 
new findings indicate that SR Ca2+ leak is exacerbated by RyR2 dephosphory-
lation, a finding opposing previous studies that implicate increased RyR2 
phosphorylation in SR Ca2+ leak (Liu et al. 2014). 
 
CASQ2 is a high capacity low affinity Ca2+ buffer in the SR, and additionally 
modulates RyR2 open probability via its interaction with triadin and junctin 
(Györke et al. 2004, Györke et al. 2008). Mutations in CASQ2 are likely to 
cause CPVT by various mechanisms (Faggioni et al. 2012). The loss of func-
tional CASQ2 may release the inhibitory effect on RyR2 and lead to spontane-
ous Ca2+ release independent of the free SR Ca2+ concentration. Secondly, the 
absence of CASQ2 SR Ca2+ buffering will increase free SR Ca2+ concentration 
and thus spontaneous Ca2+ release (Kornyeyev et al. 2012). Additionally, the 
absence of CASQ2 leads to structural SR remodelling and downregulation of 
triadin and junction, leading to spontaneous Ca2+ release (Knollmann et al. 
2006). Absence of triadin was recently linked to CPVT, highlighting its im-
portance in maintaining normal SR Ca2+ release (Roux-Buisson et al. 2012).  
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1.9.4 Management and challenges 
A CPVT diagnosis is followed by comprehensive genetic testing (RyR2 and 
CASQ2), screening of family members, and counseling (Ackerman et al. 2011, 
van der Werf et al. 2013). Patients are advised on exercise restriction, and the 
	
	
 
	
-blocker treatment is started, 
typically with a long-acting compound that lacks sympathomimetic activity, 
such as nadolol (Hayashi et al. 2009). Also propranolol is widely used. For 
prevention of arrhythmias, it is important to titrate 
-blocker to the highest 
tolerable dose. 
-blocker therapy event rates remain significant with 
estimated 8-year rates for arrhythmic events at 37.2%, near fatal events at 
15.3%, and fatal events at 6.4% (van der Werf et al. 2012). Carvedilol may be 
a good alternative in the future, based on its recently discovered ability to di-
rectly decrease RyR2 open probability (Zhou et al. 2011).  
 
Importantly, if arrhythmic events occur on -blocker therapy, treatment must 
be boosted. 

-blocker therapy with flecainide is recommended 
as the next step (van der Werf et al. 2013). Flecainide was found to directly 
inhibit RyR2, and its ability to suppress arrhythmic events in small clinical 
studies is encouraging (Watanabe et al. 2009, van der Werf et al. 2011). Alt-
hough the LTCC-!

		

"	-blocker was effective in 
reducing ventricular arrhythmias during exercise stress testing (Swan et al. 
2005, Rosso et al. 2007), in a long term follow-up the combination failed to 
prevent significant ventricular arrhythmias (Rosso et al. 2010). Drugs of pos-
sible therapeutic value in the future include propafenone (Hwang et al. 2011), 
K201 (JTV519) (Lehnart et al. 2004a), and the CaMKII inhibitor KN-93 (Liu 
et al. 2011). 
 
If patients are not arrhythmia-free despite optimized drug therapy, left cardiac 
sympathetic denervation may be performed. In this procedure, the lower half 
of the left stellate ganglion and the thoracic ganglia Th2-4 are removed to pre-
vent norepinephrine release in the heart (Odero et al. 2010). The role of this 
technique in the management of drug-resistant CPVT remains unclear. Long-
term follow-up data are lacking, while short-term results in small sets of pa-
tients seem promising (Wilde et al. 2008, Collura et al. 2009, Schneider et al. 
2013). The technique is mastered only by a limited number of surgeons world-
wide, restricting its availability (Leenhardt et al. 2012). Some authors consider 
it the next line of treatment after optimizing drug therapy (van der Werf et al. 
2013), while others see it as an experimental approach following implantable 
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cardioverter defibrillator (ICD) treatment to reduce ICD shocks in patients 
with persistent arrhythmic storms (Liu et al. 2008). 
 
Also the role of ICD therapy is unclear. The official recommendation is to 
implant an ICD for CPVT patients with a history of sustained VT or VF, and 
to consider it for asymptomatic patients with a heavy familial burden of early 
	# 	# 
#		# 
	
 $'  #
  -
blocker therapy is an indication for ICD implantation (Epstein et al. 2013). 
However, the proarrhythmic effect of ICD shocks has recently raised concern 
(Mohamed et al. 2006, Palanca et al. 2006, Pizzale et al. 2008), and prompted 
some to recommend ICD implantation only as a last resort after other available 
treatments have proven inadequate (Garratt et al. 2010, van der Werf et al. 
2013). Optimal ICD programming in these patients remains extremely difficult 
(Roses-Noguer et al. 2013). 
 
Factors that complicate the diagnosis and management of CPVT patients and 
their family members include highly variable disease penetrance, hence the 
lack of established genotype-phenotype correlations, and the high proportion 
of de novo mutations (Leenhardt et al. 2012). In the future improving risk 
stratification for CPVT patients and their relatives is of utmost importance. 
 
1.10   Autosomal dominant polycystic kidney disease – with a focus 
on cardiac manifestations 
1.10.1 Characteristics 
ADPKD is a genetic disease char-
acterized by the development of 
multiple bilateral renal cysts and 
numerous extrarenal manifesta-
tions (Gabow 1993, Torres et al. 
2007) (figure 10). 
 
Figure 10. Comparison of normal 
kidney anatomy with that of a poly-
cystic kidney, which is enlarged and 
contains multiple cysts in varying 
stages of development. Modified from 
www.kidney.niddk.nih.gov.
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The cysts grow in number and size, and affect renal function usually between 
the 4th and 6th decades of life. At this point the kidneys are usually very cystic 
and enlarged, Annually the total kidney volume increases by approximately 5% 
and glomerular filtration rate decreases by approximately 5mL/min (Klahr et 
al. 1995, Grantham et al. 2006). Kidney and cyst volumes are the strongest 
known predictors of renal failure. In progressed disease, a cyst-filled kidney 
can weigh 10-15kg, 100-fold the weight of a normal healthy kidney. The pro-
gression to end-stage renal disease, defined as renal failure needing replace-
ment therapy (GFR < 15mL/min/1.73m2), occurs on average during the 6th to 
8th decades of life (Hateboer et al. 1999). The disease tends to progress faster 
in men.  
 
ADPKD patients often develop cysts and other manifestations in multiple or-
gans, reflecting the systemic nature of the disease (Torres et al. 2007). Cysts 
may form in the liver, pancreas, seminal vesicles, and arachnoid membrane. 
Other extrarenal manifestations include intracranial arterial elongation and 
aneurysms, aortic root dilatation and aneurysms, diverticulosis, and hernias of 
the abdominal wall (Pirson 2010). Most of the adult patients experience renal 
pain, mainly due to infections, stones, hemorrage, and cysts (Bajwa et al. 
2004). With the availability of modern renal replacement therapies, cardiovas-
cular diseases have become a major cause of morbidity and the most common 
cause of mortality in ADPKD patients (Fick et al. 1995, Perrone et al. 2001, 
Ecder 2013). Interestingly, patients usually become hypertensive before im-
pairment of renal function. Half of the patients develop high blood pressure 
(>140/90 mmHg) before 35 years of age (Kelleher et al. 2004). Also other 
cardiovascular abnormalities manifest early in the course of the disease. 
Young patients with normal blood pressure and renal function show endotheli-
al dysfunction, impaired coronary flow reserve, increased carotid intima-media 
thickness, arterial stiffness, and biventricular diastolic dysfunction (Bardaji et 
al. 1998, Oflaz et al. 2005, Ecder 2013). Furthermore, hypertension and left 
ventricular hypertrophy commonly contribute to cardiovascular complications 
in these patients (Chapman et al. 1997). Additionally, mitral-valve prolapse is 
seen in one out of four patients (Hossack et al. 1988, Lumiaho et al. 2001).  
 
ADPKD is seen world-wide with a prevalence varying between 1 in 400 to 1 
in 4000, making it the most common inherited kidney disease (Torres et al. 
2007). Recent figures from south-west Germany put the overall prevalence of 
ADPKD at approximately 1 in 3000 (Neumann et al. 2013). Disease severity 
varies significantly between and within families, reflecting the important role 
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of modifying factors, which may be either genetic and/or environmental 
(Geberth et al. 1995, Persu et al. 2004).  
1.10.2 Genetic background 
The autosomal dominant pattern of inheritance of the disease was recognized 
more than half a century ago (Dalgaard 1957). In the 1980s the disease was 
linked to chromosome 16, but soon after it was realized that not all families 
show this linkage, suggesting that also other loci are implicated (Reeders et al. 
1985, Kimberling et al. 1988, Romeo et al. 1988). In the 1990s two disease-
causing genes were identified. Mutations in PKD1, which encodes the protein 
polycystin-1 (PC1), previously also known as transient receptor potential pol-
ycystic 1 (TRPP1), account for approximately 85% of cases (Hughes et al. 
1995). Mutations in PKD2, which encodes the protein PC2, also known as 
transient receptor potential polycystic 2 (TRPP2), account for most of the rest, 
approximately 10-15% of the cases (Mochizuki et al. 1996). Likely disease-
causing mutations can be identified in approximately 90% of patients (Rossetti 
et al. 2007). The proportion of de novo mutations is approximately 10%. A 
small amount of cases may be caused by a yet unknown locus. However, a 
recent re-analysis of PKD families failed to find evidence of a third ADPKD 
locus (Paul et al. 2013). 
 
PKD1 is located at the chromosomal locus 16p13.3 and consists of 46 exons 
(Consortium 1995, Hughes et al. 1995). Its protein product PC1 forms a mem-
brane protein with 11 transmembrane domains. The Mayo ADPKD Mutation 
Database (http://pkdb.mayo.edu) contains nearly 2000 PKD1 gene variants 
(January 2014) (Gout et al. 2007). Roughly half appear to be pathogenic, and 
most of these are nonsense or frameshift mutations, leading to truncated pro-
teins. PKD2 is located at the chromosomal locus 4q21 and consists of 15 ex-
ons (Mochizuki et al. 1996, Hayashi et al. 1997). Its product PC2 is a mem-
brane protein with six transmembrane domains. The Mayo ADPKD Mutation 
Database contains close to 300 PKD2 gene variants (January 2014). Nearly 
three quarters of them are suspected to be pathogenic, most of these as well 
being nonsense or frameshift mutations. Mutations in both genes are spread 
throughout the gene with no clear clustering to certain regions, meaning they 
are very heterogeneous and usually private, i.e. confined to a single family 
(Tan et al. 2011). PKD1 mutations lead to a more severe disease than PKD2 
mutations. The average onset of end-stage renal disease occurs during the 6th 
decade of like in PKD1 and 8th decade of life in PKD2 (Hateboer et al. 1999). 
This is due to earlier disease onset in PKD1, not to faster rate of disease pro-
40 
 
Review of literature 
Autosomal dominant polycystic kidney disease 
 
 
gression (Harris et al. 2006). The mutation type (missense versus truncating) 
does not seem to be associated with the phenotype. However, mutations locat-
ed in the 5’ (N-terminal) end of PKD1 are more commonly associated with 
vascular manifestations and more severe kidney disease (Rossetti et al. 2002, 
Rossetti et al. 2003). 
1.10.3 Mechanisms 
The role of polycystins in the heart remains poorly understood. PC1 has a long 
extracellular N-terminus, 11 transmembrane regions, and a short C-terminus 
that interacts with the C-terminus of PC2 (Hughes et al. 1995, Casuscelli et al. 
2009). It is expressed in numerous tissues, including the heart (Geng et al. 
1997, Ong et al. 1999). PC1 is mainly located on the plasma membrane, but 
may also be found in primary cilia, cytoplasmic vesicles, endoplasmic reticu-
lum, and nuclei. It interacts with numerous intra- and extracellular proteins 
(Torres et al. 2009). PC1 is normally located in adherens junctions, where it is 
thought to regulate the strength of adhesion between adjacent cells by control-
ling formation of stable adherens junctions in a process induced by a rise in 
[Ca2+]i (Boca et al. 2007, Markoff et al. 2007). However, overall PC1 function 
remains incompletely understood. 
 
PC2 is less than a fourth the size of PC1. It has short C- and N-termini and six 
transmembrane regions. Also PC2 is ubiquitously expressed, including myo-
cardial and endocardial cells (Ong et al. 1999). It forms a non-selective Ca2+-
regulated cation-channel that is mainly located on the endoplasmic reticu-
lum/SR membrane and the primary cilia, where it colocalizes with PC1 
(Vassilev et al. 2001, Koulen et al. 2002, Geng et al. 2006). In rat, PC2, but 
not PC1, was found on the sarcolemma of ventricular myocytes, suggesting it 
can function independently of PC1 (Volk et al. 2003). PC2 functions as an 
intracellular Ca2+ channel that regulates [Ca2+]i, as well as a receptor-operated 
channel on the plasma membrane and a mechanosensitive channel on the cili-
ary membrane (Qian et al. 2003, Anyatonwu et al. 2004, Tsiokas et al. 2007). 
PC2 is known to interact with numerous proteins involved in intracellular Ca2+ 
handling (Torres et al. 2009). Interestingly, the C-terminus of PC2 is shown to 
inhibit RyR2 in its open state, thus inhibiting RyR2 channel activity. In PC2-
deficient cardiomyocytes, the loss of inhibition of RyR2 by PC2 led to small 
frequent spontaneous Ca2+ transients and reduced SR Ca2+ stores (Anyatonwu 
et al. 2007). PC2 modulates also IP3R channel activity, and IP3R can activate 
PC2 channel function (Sammels et al. 2010, Mekahli et al. 2012). Syntaxin 5 
inactivates PC2, preventing endoplasmic reticulum Ca2+ leak (Geng et al. 
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2008). Of interest is the interaction of PC2 with the cytoskeleton and its com-
ponents troponin I (Li et al. 2003b), tropomyosin-1 (Li et al. 2003a), hax-1 
(Gallagher et al. 2000), and filamin (Wang et al. 2012), some of which are 
implicated in heart failure. In the progression of polycystic kidney disease, 
evidence for the important roles of [Ca2+]i and cAMP signaling is mounting 
(Torres et al. 2009). ADPKD cysts show reduced [Ca2+]i and endoplasmic 
reticulum Ca2+ stores (Xu et al. 2007). Is is thought that abnormal Ca2+ homeo-
stasis in ADPKD accounts for the accumulation of cAMP, which promotes 
cell proliferation and fluid secretion into cysts (Torres et al. 2006). 
 
To summarize, in addition to an important role in progression of kidney dis-
ease via cyst expansion and increased cell proliferation and apoptosis (Torres 
et al. 2009, Abdul-Majeed et al. 2011, Mekahli et al. 2013), Ca2+-mediated 
mechanisms may also turn out to have a role in ADPKD-associated cardiac 
pathology.  
1.10.4 Management and challenges 
Current management is aimed at preventing and treating the various complica-
tions of the disease (Torres et al. 2007). Until very recently, there have not 
been treatments that slow kidney disease progression (Grantham 2008). Man-
agement of hypertension is essential. ACE inhibitors and angiotensin receptor 
blockers may be more effective than other types of antihypertensive agents at 
preventing end-organ damage (Schrier et al. 2003). Complications that may 
need management include pain, urinary tract infections, hematuria, kidney 
stones, end-stage renal disease, intracranial aneurysms, and diverticulitis.  
 
Preclinical studies showed that the antidiuretic hormone arginine vasopressin 
and its second messenger cAMP promote cyst growth and decline of renal 
function that can be prevented when vasopressin is eliminated or its effect 
blocked (Gattone et al. 2003, Wang et al. 2008). Recently, the vasopressin V2-
receptor antagonist tolvaptan was shown to slow the increase in total kidney 
volume and decrease the decline of kidney function in ADPKD patients 
(Torres et al. 2012). There are currently over a dozen ongoing clinical trials for 
ADPKD (http://clinicaltrials.gov). Thus mechanistically relevant drugs look 
set to change the treatment of ADPKD in the upcoming decades (Chang et al. 
2012). For this to happen, a deeper understanding of the molecular level 
pathomechanisms of this systemic disease is necessary. 
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ELECTRICAL ACTIVITY AND CALCIUM 
HANDLING 
Having the right tools is necessary to study and understand cardiac physiology. 
In recent years the methodological toolkit has been strengthened by powerful 
methods that open new possibilities to deepen our understanding of how the 
heart works and fails.  
1.11   At the cellular level  
1.11.1 Patch-clamp and calcium imaging in individual cardiomyocytes  
In the 1970s, the German cell physiologists Erwin Neher and Bert Sakmann 
developed a technique to measure ion channel currents in cells by using a glass 
micropipette (Neher et al. 1978). This technique came to be known as patch-
clamp (Hamill et al. 1981), and earned Neher and Sakmann the Nobel Prize in 
Physiology or Medicine in 1991. To measure ion currents, the glass micropi-
pette, which has an opening in the range of 1μm at its tip, is brought into tight-
ly sealed contact with the cell membrane. The micropipette contains an elec-
trode and a solution of desired contents. The tight seal, formed by applying 
suction to the micropipette, electronically isolates the membrane patch from 
the external environment and enables stable recording of electric currents 
across this patch of membrane. Many variations of the patch-clamp technique 
exist. To investigate changes in current or voltage across the entire cell mem-
brane, the whole-cell patch technique is applied (Hamill et al. 1981). After 
forming a seal between the cell membrane and the micropipette, further suc-
tion is applied to rupture the patch membrane. Now the inside of the micropi-
pette, which usually contains solution matched to intracellular solution, forms 
a contiguous space with the inside of the cell. An alternative way to perforate 
many small holes into the membrane is by applying chemical agents such as 
amphotericin-B. This variation is called the perforated patch method. In cur-
rent-clamp mode, changes in voltage across the plasma membrane of the 
whole cell can be recorded as the current is held constant. Patch-clamp re-
mains the gold standard method of cellular electrophysiology. 
 
Ca2+ is a universal second messenger involved in the process of life from ferti-
lization to apoptosis. The accurate measurement of Ca2+ levels in living cells 
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has been the goal of scientists for decades. The first successful attempts were 
in the 1960s (Ridgway et al. 1967). A big leap came in the 1980s when a va-
riety of fluorescent Ca2+ indicator dyes were developed by the Tsien lab (Tsien 
1980, Grynkiewicz et al. 1985). Upon binding to Ca2+, these dyes emit fluores-
cent light, allowing the measurement of [Ca2+]i (Paredes et al. 2008, Adams 
2010). The dyes are usually loaded into cells as lipophilic acetoxymethyl (AM) 
esters. Inside the cells, esterases cleave off the AM-group, thus trapping the 
dye inside the cell and exposing its Ca2+ binding carboxyl groups. Changes in 
[Ca2+]i in individual cells or even whole organs can be imaged with fluores-
cence microscopy and sensitive cameras. These dyes have proven to be relia-
ble tools, explaining their skyrocketing popularity. Additionally, intracellular 
Ca2+ can be measured with genetically encoded indicators and calcium-
sensitive photoproteins (Brini 2008, McCombs et al. 2008). 
1.11.2 Induced pluripotent stem cells – a novel source of 
cardiomyocytes 
Physiological studies on mechanisms of genetic diseases have largely been 
based on transgenic animal models and in vitro experiments involving trans-
fection with mutated human genes. The applicability of results obtained with 
these model systems to human disease often remains uncertain. Furthermore, 
an identical genotype regarding a gene of interest can lead to large variation in 
phenotype between individuals, largely due to unknown genetic and environ-
mental modifiers. These issues have occasionally made interpretation of re-
sults obtained with traditional methods challenging, and conclusions difficult 
to draw. On the other hand, isolation and culture of human adult cardiomyo-
cytes has proved difficult.  
 
Scientists were filled with new excitement some years ago, as the Japanese 
geneticist Shinya Yamanaha and colleaques reported they could reprogram 
differentiated adult mouse cells back to a pluripotent state by using a cocktail 
of four transcription factors (Takahashi et al. 2006). These cells came to be 
known as induced pluripotent stem cells (iPSC). Very soon after this, similar 
findings were reported using adult human cells (Takahashi et al. 2007, Yu et al. 
2007). Yamanaha shared the 2012 Nobel Prize in Physiology or Medicine for 
this discovery. The ability to differentiate cardiomyocytes from iPSCs now 
enables the study of patient- and disease specific human cells in vitro (Zhang 
et al. 2009a, Mummery et al. 2012) (figure 11). It also bypasses the ethical 
issues associated with human embryonic stem cells.  
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This new technology opens a multitude of possibilities for studying inherited 
diseases. The pathomechanisms can be investigated at the cellular and molecu-
lar levels in a human cell model. IPSC-derived cells may be used as tools to 
deliver in vitro optimized personalized treatment by screening for safest and 
most effective compounds for that individual. The cells may be used for drug 
discovery and toxicology screening and to gain a deeper understanding of how 
genotype affects drug responses. This is especially relevant with cardiomyo-
cytes, as for all drugs, adverse effects on the heart are the most common cause 
of approval delay and withdrawal from the market (Mordwinkin et al. 2013).  
 
However, many issues need to be addressed before iPSC technology becomes 
a firmly established tool in these fields (Knollmann 2013, Li et al. 2013a, 
Priori et al. 2013, Sinnecker et al. 2013). Current differentiation protocols pro-
duce a heterogeneous group of cells that contain many non-cardiomyocytes as 
well as different types of cardiomyocytes (atrial, pacemaker, ventricular) at 
various stages of maturation. In addition to heterogeneity of cells produced by 
a certain iPSC-line, there is great variation between different cell lines pro-
duced from the same patient. Phenotypically the cells resemble immature fetal 
cells more than mature adut cardiomyocytes. This is demonstrated for example 
by small cell size, lack of T-tubules, depolarized resting membrane potential, 
spontaneous beating, and weak contractions (please see page 96 for details). 
Furthermore, a cell model is of limited use in studying organ-level pathologies 
such as myocardial infarction, heart failure, and developmental defects. 
Figure 11. Promises and possibilities of iPSC technology for cardiac patients. 
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Additionally, cellular reprogramming strategies hold promise for treatment of 
acquired cardiac diseases including myocardial infarction and heart failure. 
Cardiac repair and regeneration may be attempted either by cell therapy using 
iPSC-derived in vitro differentiated cardiomyocytes (Yoshida et al. 2011, 
Okano et al. 2013), or via in vivo direct reprogramming of cardiac fibroblasts 
to myocytes (Addis et al. 2013, Qian et al. 2013). However, here also many 
challenges remain. Effective in vivo reprogramming in humans still seems 
fairly distant. In addition to the issues listed above, it also raises safety con-
cerns about tumorigenicity and arrhythmogenicity. 
1.12   At the tissue level 
1.12.1 Calcium and action potential imaging 
In addition to single cell measurements, fluorescent Ca2+ indicators can be used 
to record changes in [Ca2+]i in tissue samples or even whole organs. Similarly, 
APs can be recorded optically using voltage-sensitive dyes, also known as 
potentiometric dyes (Cohen et al. 1978). These dyes attach to the cell mem-
brane and respond to a change in electric potential across the membrane with a 
change in the intensity of fluorescent light they emit. This can be recorded 
using fluorescent microscopy and sensitive camera equipment. The advantage 
of voltage-sensitive dyes compared to patch-clamp techniques is the possibility 
to study AP conduction (speed and direction) in multi-cellular preparations 
with a non-invasive method. This makes them attractive tools in cardiac re-
search (Herron et al. 2012). Drawbacks include the special recording equip-
ment and laborious optimization of protocols needed mainly due to weakness 
of the fluorescent signal. Also issues posed by motion artifacts and photody-
namic effects need to be addressed. A further alternative for AP measurements 
is the multi/microelectode array method (Spira et al. 2013). 
1.12.2 Monophasic action potential recordings 
The first account of MAP recordings dates back to the 19th century, when elec-
trical activity was measured in the frog ventricle (Burdon-Sanderson 1884). 
Also subsequent techniques relied on producing an injury to the region where 
MAPs were recorded from. Then it was discovered that simply pressing the 
electrode against the heart is sufficient to record stable MAPs (Jochim et al. 
1935). However, this discovery was practically forgotten after cardiac APs 
were first recorded from single cells (Draper et al. 1951). In the 1960s and 
early 70s MAPs were recorded for the first time in humans (Korsgren et al. 
1966). The technique relied on suction to maintain tight contact between the 
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catheter tip and the endocardium, predisposing to air emboli and mechanical 
injury of the myocardium. The modern contact electrode technique was devel-
oped in the early 1980s by Franz and colleagues, enabling safe prolonged 
measurement of local electrical activity in the heart in vivo (Franz 1983).  
 
Typically, MAPs are recorded by introducing the MAP catheter via femoral 
vein into the right ventricle, or alternatively via femoral artery into the left 
ventricle (Franz 1991). Under fluoroscopic guidance, the catheter tip is gently 
brought into contact with the endocardium at a perpendicular angle, and MAPs 
generally between 10 and 50 mV in amplitude are recorded for up to several 
hours (figure 12). The tip of the catheter contains a silver-silver chloride MAP 
electrode. A silver-silver chloride MAP reference electrode is located 5mm 
proximally from the tip. The location of the platinum pacing electrodes be-
tween the MAP electrodes allows low capture thresholds and minimizes pac-
ing artifacts. The catheter tip is flexible for safety, and can be controlled with a 
thumb lever by the operator. The MAP electrode records electrical activity 
from a region in its vicinity, likely from a distance of a few millimeters, en-
compassing a group of cells (Franz 1999). The MAP waveform is almost iden-
tical to that of an intracellularly recorded AP, neatly filling the gap between 
basic electrophysiology and more traditional clinical recordings, such as ECGs 
(Moore et al. 2007). In addition to research purposes, MAP recordings have 
many uses in the clinical setting. These include determining effects of drugs, 
heart rate, and rhythm on APD and refractoriness. Afterdepolarizations can be 
identified, ablation guided, and the viability of the myocardium assessed dur-
ing and after ablation. MAPs can detect myocardial ischemia and APD disper-
sion. Futhermore, MAP recording can be a useful tool in overdrive pacing of 
atrial flutter to prevent driving the atria into fibrillation. 
 
 
 
Figure 12. MAP 
recording from the 
right ventricular 
septum in a 10-year-
old male.  
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1.13   At the organism level 
1.13.1 Electrocardiograms 
The ECG has been a cornerstone of cardiology for over a century (Einthoven 
1903). It was the Dutch physiologist Willem Einthoven who, based on previ-
ous work, developed the method, named the deflections, and described chang-
es in the ECG under various pathological conditions. For this, he earned the 
Nobel Prize in Physiology or Medicine in 1924. 
 
The modern 12-lead ECG normally consists of six precordial leads, three limb 
leads, and three augmented limb leads. The unipolar precordial leads (V1-6) 
are placed on the chest and view the heart in the horizontal plane. The bipolar 
limb leads (I-III) are placed on the extremities: I measures the voltage between 
the left arm and the right arm, II between the left leg and the right arm, and III 
between the left leg and the left arm. The unipolar augmented limb leads are 
derived from the three limb leads. In aVR, the right arm is the positive elec-
trode, the left arm and the left leg make up the negative electrode. With similar 
logic, in aVL the positive electrode is the left arm, and in aVF the positive 
electrode is the left leg. The limb and augmented limb leads view the heart in 
the frontal plane. Therefore, leads II, III, and aVF are inferior leads that view 
the heart from below. Leads I, aVL, V5-6 are lateral leads that view the heart
Figure 13. The precordial leads view the heart in the horizontal plane, as shown on the 
left, whereas the limb and augmented limb leads view the heart in the frontal plane, as 
shown on the right. 
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from the left. Leads V1-4 are anterior leads, leads V1-2 look at the right ven-
tricle and leads V3-4 view the interventricular septum (figure 13). When a 
wave of depolarization is approaching the positive electrode, there is a positive 
deflection on the ECG. Conversely, when depolarization is moving away from 
the positive electrode, the deflection is negative. During repolarization, the 
deflections are in the opposite direction, meaning a wave of repolarization 
approaching a positive electrode will cause a negative deflection. The ampli-
tude of the deflection is also proportional to the mass of the tissue, therefore 
Figure 14. A. Normal 12-lead ECG in a 32-year-old male PhD candidate. B. Precordi-
al leads in the same individual showing a PVC (arrow), perhaps a sign of stress related 
to the upcoming PhD defense. C. Nomenclature of essential ECG waves, segments, 
and intervals. 
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the much larger ventricles (especially the left one) cause larger defletions than 
the smaller atria. Because ventricular depolarization progresses from endocar-
dium to epicardium, whereas repolarization progresses from epicardium to 
endocardium, the deflections caused by both events are toward the same direc-
tion. 
 
The depolarization of the atria results in a P-wave. This is followed less than 
200 ms later by the depolarization of the ventricles, which is seen on the ECG 
as the QRS-complex. This is followed by repolarization of the ventricles, 
showing on the ECG as a T-wave. Atrial repolarization is hidden among the 
QRS-complex. Occasionally, the T-wave is followed by a small U-wave, the 
origin of which is debated. A 12-lead ECG and the names of its deflections are 
shown in figure 14. 
1.13.2 Alternans and variability of repolarization 
Ventricular repolarization is manifested on the ECG as a T-wave. Its morphol-
ogy is a reflection of the heterogeneous AP morphologies across the ventricu-
lar wall (Yan et al. 1998). Studies on ventricular wedge preparations have 
revealed these intramural differences in AP morphology (Antzelevitch 2006). 
Cells on the ventricular epicardium have a prominent phase 1 of the AP and 
short APD. They are the last to depolarize, but the first to repolarize. Endocar-
Figure 15. A. A simplified sketch showing how heterogeneity of repolarization across 
the ventricular wall leads to formation of the T-wave on the surface ECG. Epi = epi-
cardial cells, Endo = endocardial cells, M-cell = mid-myocardial cells. Modified from 
(Yan et al. 1998). B. A simplified sketch showing APD alternans and corresponding 
exaggerated T-wave alternans on the surface ECG. 
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dial cells lack a prominent phase 1 of the AP. Cells located deep inside the 
ventricle wall are called M-cells. They are characterized by a prominent phase 
1, and their APs have the ability to prolong significantly with decreasing heart 
rate and the influence of some drugs (Sicouri et al. 1991). The T-wave begins 
as the AP plateaus of epicardial and M-cells separate (figure 15A). The peak 
of the T-wave is marked by the completion of epicardial repolarization. Intra-
mural voltage gradients become fully extinguished as the M-cells are fully 
repolarized. This is when the T-wave ends.  
 
Alternans of intracellular Ca2+ that leads to alternans of APD manifests on the 
surface ECG as T-wave alternans (TWA) (figure 15B) (Pruvot et al. 2004, 
Laurita et al. 2008a). TWA is defined as a beat-to-beat alternation in T-wave 
morphology (shape, amplitude, timing). Often, the definition includes alterna-
tion of the ST-segment, T- and U-waves, and is referred to as repolarization 
alternans (Narayan 2006). The first descriptions of macrovolt TWA date back 
a hundred years, to the early days of the ECG (Lewis 1911). This type of mac-
roscopic alternans is rare, and from the beginning it was clearly associated 
with cardiac pathology. In the 1980s sensitive methods to measure microvolt 
(i.e. not detectable by direct visual inspection) TWA were developed (Adam et 
al. 1984, Smith et al. 1988). These studies found TWA to associate with VF. 
Today, TWA has been shown to predict ventricular arrhythmias and SCD in 
numerous patient groups (Shusterman et al. 2006, Calo et al. 2011). However, 
also negative findings are reported, and the controversial clinical utility of 
TWA provokes continued debate (Gupta et al. 2012). 
 
The search for ECG parameters as predictive markers for arrhythmia risk is the 
focus of intense research efforts. Recently, also non-alternating beat-to-beat 
variability of repolarization has received attention (Oosterhoff et al. 2011, 
Varkevisser et al. 2012). Such variability is usually quantified as short-term 
variability (STV) of APD or the QT interval over a period of 30 – 60 beats. 
Increased STV has been shown to be a superior predictor of drug-induced 
arrhythmogenesis than QT prolongation (Abi-Gerges et al. 2010). Additionally, 
increased STV of QT interval has recently been associated with proarrhythmia 
in long QT syndrome patients and dilated cardiomyopathy (DCM) patients 
with heart failure (Hinterseer et al. 2008, Hinterseer et al. 2010). As many 
questions remain unanswered, the search for optimal prognostic markers for 
arrhythmia risk goes on (Shusterman et al. 2009). 
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1.13.3 Zebrafish as a model organism to study human cardiac 
disease 
The last two decades have seen a huge surge in popularity of using zebrafish 
(Danio rerio) as a model for human disease in biomedical research. Zebrafish 
have proved a useful model to study heart development, mechanisms of inher-
ited and acquired cardiac disease, and in drug development and cardiac toxici-
ty screening (Heideman et al. 2005, Dahme et al. 2009, Bakkers 2011, MacRae 
2013). Advantages and disadvantages of zebrafish in cardiac research are 
listed in table 1.  
 
Table 1. Advantages and disadvantages of using zebrafish to study cardiac disease. 
ADVANTAGE EXPLANATION 
Speed Hundreds of eggs can be collected on one day's notice. Fish devel-op rapidly: heart beat in 1 day, fully developed heart in 2 days 
External development Allows direct observation of the developing embryo by using nor-mal light microscopy 
Optical transparency 
Non-invasive observation of heart and its function, including heart 
rate, contractility, cardiac output, blood flow velocity by using 
normal light microscopy 
Survival without  
circulation 
Embryonic fish survive for days without circulation, sufficient 
oxygen and nutrients are supplied by diffusion, allows study of 
severe cardiac phenotypes 
Similar cardiac  
physiology 
Heart rate (100–170/min) and action potential duration are more 
similar to human values  than in rodents. However, please see 
limitations on page 98. 
Simple administration 
of drugs Many drugs can be applied directly to the bath water 
Genetic methods Fully sequenced genome. Transgenic fish are increasingly available. Gene silencing with antisense oligos is a well established method 
Affordability Costs of husbandry and maintenance are very low compared to mammals 
DISADVANTAGE EXPLANATION 
Not a mammal 
Zebrafish is a non-mammalian vertebrate. Results must be inter-
preted with caution, exciting findings should be confirmed with 
mammalian models 
Smaller toolkit Availability of cell lines, reagents, and transgenic lines is still poor-er than in well established rodent models 
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Zebrafish originate from freshwater streams in South-East Asia. Females can 
lay hudreds of eggs weekly. After external fertilization, the development is 
remarkably rapid. Heart beat initiates 1 day post fertilization (dpf) and the 
heart is fully formed at 2 dpf. At this stage the fish are 1 – 2 mm long and their 
heart is approximately 150 μm in diameter. The zebrafish heart is two-
chambered, consisting of an atrium and a ventricle (figure 16) (Menke et al. 
2011). The embryos hatch from the chorion 2 – 3 dpf and begin their larval life. 
After their internal yolk reserve is depleted in approximately a week, the 
young fish must start catching their own food. Zebrafish reach adulthood at 
three months. The fish grow approximately 3 – 4 cm long and weigh close to 1 
g. They can live until approximately five years of age, but for research purpos-
es adult fish aged 6 – 18 months are typically used (figure 17). 
 
Figure 16. A. Zebrafish larva at 9 dpf. 
Image by Ivana Kuo, Yale University. B-
C. Close-up images under a light micro-
scope of an embryonic zebrafish heart at 2 
dpf. Outlines of the atrium and ventricle 
are marked, demonstrating the difference 
in chamber size between diastole and 
systole. Images by Juuso Sirén, University 
of Helsinki. 
Figure 17. Adult zebrafish. Photo by 
Henri Koivula, University of Helsinki. 
 
The genetic tractability of zebrafish is a big factor in its current popularity. It is 
ideal for phenotype-driven, forward genetics methods. Mutagenesis screens 
53
 
Review of literature 
MODELS AND TOOLS TO STUDY THE HEART 
 
 
have been performed for over a decade (Amsterdam et al. 1999). Chemicals, 
retroviruses, or transposons are used to generate mutations that are then 
screened and selected for interesting phenotypes (Milan et al. 2008). The caus-
ative gene mutations can then be identified with positional cloning. These 
types of screens are an unbiased way to identify novel genes implicated in 
cardiac disease. Indeed, numerous cardiac phenotypes and mutations have 
been identified, providing models for mechanistic and therapeutic studies 
(Chico et al. 2008, Dahme et al. 2009). Conversely, a known gene of interest 
can be manipulated to study phenotypic and physiologic consequences. Such 
reverse genetic methods are most commonly applied by injection of antisense 
oligonucleotides (morpholinos) into fertilized eggs (Nasevicius et al. 2000, 
Eisen et al. 2008). 
 
The morpholino will typically block target mRNA translation and result in 
absence of the target protein for 3 – 5 days. Similarly, desired mRNA may be 
injected to overexpress a gene of interest. This simple method enables studies 
on the impact of a single gene on development and physiology in a fast, af-
fordable way. This well established method is a logical next-step to study ef-
fects of candidate genes identified in humans in e.g. genome-wide association 
studies. The recent years have also seen rapid development of targeted muta-
tion and gene-inactivation methods, as well as the emergence of powerful 
transgenic techniques that allow temporal and spatial control of gene expres-
sion in zebrfish (Staudt et al. 2012). 
 
Zebrafish have been used to model a wide variety of cardiac diseases. Congen-
ital heart anomalies are the most common birth defects in humans, occurring in 
approximately 1% of live births. For example, the zebrafish gridlock mutant, 
which harbors a mutation in the hey2 gene, offers a model for aortic coarcta-
tion (Weinstein et al. 1995). Importantly, an in vivo small-molecule screen 
identified compounds that rescue the disease phenotype by upregulating vascu-
lar-endohelial growth factors (Peterson et al. 2004). Furthermore, an illustra-
tive example of the power of zebrafish as model is the discovery of nexilin 
function and its role in disease (Hassel et al. 2009). Nexilin, previously of 
unknown function, was identified as a Z-disk protein, and its inactivation in 
zebrafish using morpholinos led to a DCM phenotype with dilated cardiac 
chambers and heart failure. Next, human DCM patients were sequenced and 
mutations in nexilin identified. Overexpression of these human nexilin muta-
tions in zebrafish recapitulated the human disease phenotype. Additionally, 
zebrafish offers a model for cardiac arrhythmia (Milan et al. 2008). For exam-
ple, heterozygous mutations in the kcnh2 gene, which encodes one of the po-
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tassium channel subunits important in repolarization, lead to prolonged re-
polarization (Arnaout et al. 2007). Conversely, gain-of-function mutations in 
the same gene lead to shortened depolarization (Hassel et al. 2008). These 
mutants offer models to study human long and short QT syndromes. Im-
portantly, zebrafish respond to QT interval affecting drugs comparably to hu-
mans. When given 23 drugs known to prolong the QT interval in humans, 22 
of these resulted in a similar QT prolongation in zebrafish (Milan et al. 2003). 
Remarkably, zebrafish are capable of fully regenerating their heart following 
injury, hence providing an exciting model to study regeneration (Poss et al. 
2002). The first reports used an amputation model, where approximately 20% 
of the ventricle is excised from the apex. More recently, a cryoinjury-induced 
myocardial infarction model has been introduced (Chablais et al. 2011, 
Gonzalez-Rosa et al. 2011). Application of a metal-probe cooled in liquid ni-
trogen results in the death of approximately 20% of the ventricular myocytes. 
After both types of injuries, essentially full regeneration ensues in one month.  
 
The above mentioned snap shots demonstrate the versatility and robustness of 
zebrafish as a model organism in cardiac research. 
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I Investigate the mechanisms of ventricular arrhythmia in CPVT by 
examining cardiac electrophysiology in vivo and intracellular Ca2+ 
handling in vitro. 
 
 
II Decipher the cellular level pathomechanims of CPVT by studying 
electrophysiology and intracellular Ca2+ handling in human iPSC-
derived cardiomyocytes generated from a CPVT patient carrying a 
RyR2 mutation.  
 
 
III Expand mechanistic studies on cardiomyocytes. Explore depolari-
zation and repolarization in clinical MAP recordings and ECGs of 
CPVT patients for corresponding manifestations of abnormalities 
discovered in cell studies.  
 
 
IV Investigate cardiac function and potential mechanisms of dysfunc-
tion in a zebrafish model of PKD with in vivo and ex vivo tech-
niques. Determine the association between PKD and heart failure in 
humans.
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1 Clinical data 
1.1 MAP recordings (Studies I – III) 
We recruited patients from three Finnish CPVT families that carry known 
mutations in RyR2 (P2328S, Q4201R, and V4653F). Out of the 22 affected, 
over 10-year-old subjects, six refused the electrophysiological study and one 
had another serious medical condition. Right cardiac catheterization with MAP 
recording was performed in the remaining 15 patients, and in 12 age-matched 
controls. The control subjects were recruited from patients being electrophysi-
ologically evaluated after a catheter ablation of accessory AV pathways. 12 
consecutive patients were chosen for MAP recording, which was performed at 
the end of the routine electrophysiological evaluation. All subjects had normal 
QT intervals, structurally normal hearts, and were not taking any medications 
known to affect cardiac repolarization. The control subjects were 18 – 50 years 
 	"

 	!-blockers. In CP$'	
 -blockers were dis-
continued at least five drug half-lives prior to a bicycle ergometer exercise test, 
which was performed one day before the MAP recording. All protocols were 
carried out according to institutional guidelines. The research protocol was 
approved by the Ethics Review Committee of the Department of Medicine, 
University of Helsinki. All study subjects provided written informed consent. 
 
To study APs and cellular mechanisms of arrhythmias in vivo, MAPs were 
recorded by introduction of a bipolar silver–silver chloride catheter (model 
006248, Bard Inc., USA) through the femoral vein. The catheter was attached 
to the right ventricular septum under fluoroscopic guidance. Additionally, 
three quadripolar electrophysiological catheters (Bard Inc.) were placed in the 
right atrium, the AV junction, and the right ventricular apex. Blood pressure 
from the femoral artery was monitored with a fluid manometer. The MAP 
signal was amplified and filtered at 0.05 – 250 Hz. Blood pressure and 12-lead 
ECG were stored digitally at a sampling rate of 1 kHz (Cardiolab, Prucka En-
gineering, USA). 
 
Stable MAP signal, indicated by noiseless stable amplitude and isopotential 
baseline at diastole, was recorded in all patients. MAPs were recorded during 
sinus rhythm and atrial pacing at cycle lengths of 600, 500, and 400 ms. First, 
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a baseline was recorded, followed by infusion of incrementally increasing 
concentrations of epinephrine. For safety reasons, the maximal infusion rate of 
epinephrine was maintained at 0.05 μg/kg of body weight, while carefully 
monitoring possible arrhythmias.  
 
Custom-made non-commercial software was used for analysis of MAPs. 
EADs were defined as low-amplitude afterdepolarizations that occur before 
the completion of repolarization, during phase 2 or 3 of the AP, and have a 
	
?\^


_ DADs were defined as low 
amplitude afterdepolarizations occurring after completion of repolarization. To 
be included in the analyses, the minimum allowed amplitude of a DAD was 
0.2 mV and 3% of the previous AP amplitude for at least five consecutive 
beats. DAD coupling interval was measured from the upslope of the previous 
AP to the peak of the DAD. The diastolic upslope of the DAD was calculated 
by measuring the mean rate of rise (dV/dt) of the ascending limb of the DAD, 
averaged over three consecutive beats. 
 
For study II, data were available on three RyR2-P2328S patients and three 
healthy controls. In study III, these same six subjects’ MAPs were evaluated 
for variability and alternans. APD was measured at 50% and 90% of repolari-
zation (APD50 and APD90). STV during 30 consecutive beats was calculated 
with the formula '$`{|}|{  \"

 ‘n’ represents the beat 
number and ‘D’ represents APD50 and APD90. APD alternans was defined as 
an absolute difference ? " 	 
	-to-beat alternating pattern between 
consecutive odd and even numbered APDs that persisted for a minimum of ten 
consecutive beats. 
1.2 24h ECG recordings (Studies II and III) 
We recruited 19 patients from two Finnish families with known mutations in 
RyR2. The main clinical data on these patients have been published previously 
(Viitasalo et al. 2008). We studied thirteen patients from a family with a RyR2-
P2328S mutation, of whom five had exercise-related syncope and three had 
cardiac arrest in their medical history. Six patients from another family with a 
RyR2-V4653F mutation were also studied. Three of them had a history of ex-
ercise-related syncope and two had suffered cardiac arrest. 24h ECGs were 


-blockers, which were discontinued in 17 out of the 19 patients 
at least five drug half-lives before start of the ECG recording. Two asympto-
matic CPVT patients were not receiving -blocker therapy. After completion 
of the 24h 
		

-blocker therapy. Seven 
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RyR2-P2328S (three with syncope, two with cardiac arrest) and five RyR2-
V4653F (two with syncope, two with cardiac arrest) patients repeated a 24h 
ECG on -blocker therapy. Five patients refused the second 24h ECG record-
ing. Gender- and age-matched control subjects with available 24h ECGs were 
chosen from a database of genotyped healthy unaffected family members of 
long QT syndrome patients. None of the 19 control subjects were taking -
blockers. 
 
All study subjects had normal echocardiography findings and serum electro-
lyte levels, and none were taking medications known to affect cardiac repolar-
ization. All were in sinus rhythm without bundle-branch blocks. The study 
subjects were instructed on following normal daily activities during the record-
ing. The study complies with the Declaration of Helsinki. The study was ap-
proved by the Ethics Review Committee of the Department of Medicine, Uni-
versity of Helsinki. All study subjects provided written informed consent.  
 
Commercial tape recorders and software (Marquette Electronics Inc., USA) 
were used to record and perform initial analysis by labeling the QRS-
complexes to normal, ventricular extrasystoles, or aberrant complexes. Further 
analysis of the 24h ECGs was performed with custom-made non-commercial 
software. Raw unsampled and unaveraged signal from the modified precordial 
lead V5 was used for all analyses. The baseline was corrected with a cubic 
spline baseline fitted to the PQ intervals of each beat. QRS onset was defined 
as the time instant where the signal amplitude of the envelope / hilbert trans-
form of the high pass filtered signal exceeds the average of the predefined 
noise interval with five standard deviations. The T-wave apex was defined as 
the peak of the parabola fitted to the highest amplitude change after the QRS. 
The T-wave end was defined as the time instant when the steepest tangent after 
the T-wave apex crosses the baseline. To improve the accuracy of T-wave 
offset identification, low amplitude T waves (-0.1 – 0.1 mV) were excluded. 
The maximum allowed noise level was set to 0.05 mV and the minimum sig-
nal-to-noise ratio was set to 30. Premature beats were rejected according to 
Marquette software’s criteria. Additionally, the maximum allowed RR interval 
difference between consecutive beats was set to 30%. Outliers were identified 
and excluded by plotting the QT interval values against the preceding respec-
tive RR intervals.  
 
To assess non-alternating beat-to beat variability, STV during 30 consecutive 
beats was calculated with the formula '$`{|}|{\"

‘n’ 
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represents the beat number and ‘D’ represents the duration of RR, QT-apex, 
QT-end etc. The QT variability index (QTVI) was calculated from consecutive 
1000 second segments with the formula QTVI=log10[(QTv/QTm
2)/(HRv/HRm
2)], 
where QTv is the QT interval variance, QTm is the QT interval mean, HRv is 
the heart rate variance, and HRm is the heart rate mean (Berger et al. 1997).  
 
TWA was analyzed from a time window set to 100 – 400 ms from the trigger 
point and for U-wave alternans (UWA) to 0 – 200 ms after the end of the T-
wave. Alternans in the latter window was interpreted as UWA without identi-
fying the U-waves. TWA and UWA were calculated with two algorithms, a 
modified moving average (MMA) algorithm and a complex demodulation 
(CDM) algorithm. The MMA algorithm is based on finding the maximum 
amplitude difference between moving averages of even and odd beats 
(Nearing et al. 2002). The CDM algorithm is a modification of the spectral 
method (Smith et al. 1988, Rosenbaum et al. 1994). In CDM the alternans 
voltage is defined from the power spectra at a 0.5 1/beat frequency and cor-
rected with a noise estimate from a 0.42 – 0.46 1/beat frequency range. In 
CDM the spectral method is modified by defining the spectral components by 
filtering demodulated beat-to-beat time-series with an infinite impulse re-
sponse type low-pass filter (4th order Butterworth type IIR filter) instead of a 
finite impulse response type filter that is used as a window function in fast 
Fourier transform. All the other parts of the CDM and the spectral method 
algorithms are identical. To increase reliability of the CDM method, only beats 
with an alternans ratio over three, i.e. beats where the power of the alternans 
frequency was at least three standard deviations greater than the estimated 
mean noise, were included in the analyses. Data were calculated for all accepted 
beats and expressed at RR steps of 10 ms for RR intervals from 500 to 1200 ms. 
 
For study II, T1-, T2-, and U-waves were defined as previously reported 
(Aizawa et al. 2006, Viitasalo et al. 2006, Viitasalo et al. 2008). T1-wave was 
defined as the first peak during repolarization. T2-wave was defined as such a 
second peak during repolarization that occasionally merges with the T1-wave. 
A U-wave was defined as a second or third peak during repolarization that 
never merges with the T1 wave. 
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1.3 The Mayo ADPKD database (Study IV) 
The Mayo ADPKD Mutation Database (Rochester, Minnesota, USA) collects 
data on ADPKD patients (http://pkdb.mayo.edu). We examined the database in 
2010, when it contained information on 2620 ADPKD patients, including 374 
genotyped patients with identified PKD mutations (307 with PKD1 and 67 
with PKD2 mutations). To investigate the association of ADPKD with heart 
failure, we decided to look for cases of idiopathic dilated cardiomyopathy 
(IDCM) among the patients in the database. The diagnosis of ADPKD in the 
presence of family history is based on Ravine’s criteria, shown in table 2 
(Ravine et al. 1994, Pei et al. 2009). In patients without a family history of 
ADPKD, diagnosis is based on at least 20 bilateral kidney cysts in the absence 
of clinical findings that would suggest a different cystic disease. A diagnosis 
of IDCM was based on left ventricular ejection fraction < 40%, exclusion of ?
50% obstruction in any coronary artery, exclusion of myocarditis, exclusion of 
a primary or a secondary heart muscle disease, and exclusion of stage 4 or 5 
chronic kidney disease. Direct sequencing was used to screen for mutations in 
the coding and flanking intronic regions of PKD1 and PKD2, as reported pre-
viously (Rossetti et al. 2007, Rossetti et al. 2009). The research protocol was 
approved by the Mayo Institutional Research Board as part of a study of geno-
type–phenotype correlations in PKD. All participants provided informed con-
sent. 
 
              Table 2. Ravine’s ultrasonographic diagnostic criteria for ADPKD. 
Patients with a family history of ADPKD1 
Years of age kidney cysts 
< 30 	
	
	
	
 
30 - 59  2 cysts in each kidney 
 	
	
 
Patients with a family history of ADPKD of unknown genotype 
Years of age kidney cysts 
15 - 39 
	- or bilateral) 
30 - 59 	
	
 
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2 Cell models 
2.1 HEK 293 cells (Study I) 
2.1.1 Site-directed mutagenesis and RyR2 expression 
To study the effects of the RyR2 mutations P2328S and V4653F on cellular 
Ca2+ handling, these point mutations were generated with a Chameleon Dou-
ble-Stranded, Site-Directed Mutagenesis Kit (Stratagene, USA) in small frag-
ments of RYR2 cDNA. Fragments with these mutations were then subcloned 
back to their original positions in full length RyR2 cDNA in expression vectors. 
For expression of RyR2, cultured HEK 293 cells were transfected with the 
RyR2 cDNA with the Ca2+ phosphate precipitation method. 
2.1.2 Calcium imaging 
One day after transfection, the HEK 293 cells were imaged using confocal 
microscopy. The Ca2+ indicator dye Fluo-3 AM (Molecular Probes, The Neth-
erlands) was used to load the cells for 30 minutes, followed by a 20 minute 
period of dye de-esterification, and imaging using an inverted microscope 
(Nikon Eclipse TE300, Japan) equipped with a confocal imaging system (Ultra 
View, PerkinElmer Life Sciences, UK). The images were recorded with a 
CCD-camera at 10 frames per second at room temperature in Tyrode’s solu-
tion containing 1.8 mM Ca2+.  
 
For recording, a view with 10 – 20 cells was chosen. After a baseline record-
ing, the cells were stimulated with 5 mM caffeine or a cAMP analoque (dioc-
tanyol cAMP) by rapidly exchanging the bath solution. The data were ana-
lyzed offline and [Ca2+]i was quantified as described previously (Lipp et al. 
2000). 
2.2 Induced pluripotent stem cell-derived cardiomyocytes (Studies 
II and III) 
2.2.1 Generation of patient-specific iPSCs 
The iPSC lines were generated as described previously (Takahashi et al. 2007). 
Fibroblasts harvested from a 25-year-old male with symptomatic CPVT due to 
a RyR2-P2328S point mutation were used to generate two iPSC lines. Two 
control cell lines were generated, one from foreskin fibroblasts, and the other 
from skin fibroblasts of a healthy 55-year-old female. The research protocol 
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was approved by the Ethics Committee of the Pirkanmaa Hospital District. All 
study subjects provided written informed consent. 
2.2.2 Characterization of iPSC lines 
Genomic sequencing to confirm the presence of the heterozygous RyR2-
P2328S mutation in the CPVT iPSC lines, and its absence in the control iPSC 
lines, was performed with direct RyR2 exon 46 sequencing of polymerase 
chain reaction (PCR)-amplified DNA. Karyotypes of the iPSC lines were de-
termined with standard G-banding chromosome analysis. Reverse transcription 
PCR was used to determine endogenous and exogenous gene expression in the 
iPSC lines. For immunocytochemistry, fixed iPSCs were stained with primary 
antibodies for SOX2, NANOG, OCT3/4, stage-specific embryonic antigen 
(SSEA-4), and tumor-related antigens TRA-1-60 and TRA-1-81. IPSCs spon-
taneously form three-dimensional clusters of cells, termed embryoid bodies. 
Embryoid bodies were maintained for five weeks. The expression of markers 
characteristic for the three embryonic germ layers, ectoderm (Nestin), endo-
derm (AFP), and mesoderm (a-cardiactin) were identified in embryoid bodies 
with reverse transcription PCR. Finally, the pluripotency of the iPSC lines was 
assessed in vivo by studying teratoma formation. Nude mice were injected 
under the testis capsule with iPSCs and tumor samples were collected eight 
weeks later. Fixed sections were stained with hematoxylin and eosin. 
2.2.3 Differentiation and characterization of cardiomyocytes 
IPSCs were differentiated into cardiomyocytes in a co-culture with murine 
visceral endoderm-like (END-2) cells, as described previously (Mummery et 
al. 2003). Beating cell colonies were excised mechanically and dissociated 
with collagenase. Single spontaneously beating cardiomyocytes were stained 
with antibodies for the cardiac markers troponin T and connexin 43. RNA 
from cardiomyocytes was isolated, and used to quantify expression of troponin 
T, RyR2, SERCA2a, LTCC (Cav1.2), PLB, and NCX. GAPDH was used as a 
housekeeping gene. 
2.2.4 Calcium imaging 
In study II, dissociated cardiomyocytes were loaded with the ratiometric Ca2+ 
indicator dye Fura-2 AM (Invitrogen, Molecular Probes, USA) for 30 minutes, 
followed by 30-minute de-esterification. The coverslip containing the cells 
was transferred to a recording chamber equipped with pacing electrodes 
(Warner Instruments, USA). The cells were perfused with Tyrode’s solution 
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(137 mmol/L NaCl, 5.0 mmol/L KCl, 0.44 mmol/L KH2PO4, 2.0 mmol/L 
CaCl2, 1.2 mmol/L MgCl2, 5.0 mmol/L glucose, 20 mmol/L HEPES, 4.2 
mmol/L NaHCO3, 1.0 mmol/L Na-puryvate. The pH was adjusted to 7.4 with 
NaOH). All steps were conducted at +37°C. Imaging was conducted on an 
inverted IX70 microscope (Olympus Corporation, Germany) equipped with an 
ANDOR iXon 885 CCD camera (Andor Technology, Northern Ireland). A 
UApo/340 x20 air objective (Olympus Corporation, Germany) was used to 
visualize the cells, and images were recorded at approximately 10 frames per 
second. The perfusate temperature was maintained with an inline heater con-
nected to a control unit (Warner Instruments, USA). A Polychrome V light 
source (TILL Photonics, Germany) was used to excite the Fura-2 at wave-
lengths of 340 nm and 380 nm. Emission was recorded at 505 nm. The cells 
were electrically paced using a stimulator (Digitimer, USA) at a frequency 
slightly higher than their spontaneous beating frequency. The cells were stimu-
lated with a perfusion of 1 μM epinephrine. The SR Ca2+ content was estimat-
ed by releasing SR Ca2+ with an instantaneous high concentration (40 mM) 
caffeine pulse. At the end of the experimental protocol, the viability of cells 
was confirmed by observing spontaneous beating. For fluorescence measure-
ments, regions of interest were selected on spontaneously beating cells. Back-
ground noise was subtracted and changes in fluorescence intensity over time 
F) were normalized to resting fluorescence levels (F0). The fluorescence 
values are presented as ratiometric values of F340/F380 or as F/F0. Analysis of 
data was performed, blinded to the genotype of the cells, with Clampfit soft-
ware (Molecular Devices, USA). 
 
In study III, coverslips containing the dissociated cardiomyocytes were loaded 
with the Ca2+ indicator dye Fluo-4 AM (Invitrogen, USA) for 30 minutes at 
+37°C in Tyrode’s solution (136 mmol/L NaCl, 5.4 mmol/L KCl, 0.3 mmol/L 
NaH2PO4, 1.8 mmol/L CaCl2, 1 mmol/L MgCl2, 5 mmol/L glucose, 10 
mmol/L HEPES, 2% BSA, pH adjusted to 7.4 with NaOH). After a 30-minute 
de-esterification at +37°C, the coverslips were transferred to a recording 
chamber equipped with electrodes for field stimulation (Warner Instruments, 
USA). Ca2+ imaging was conducted at +37°C on an inverted microscope using 
a UPlanSAPo x20 air objective (Olympus Corporation, Germany). The tem-
perture inside a transparent plastic housing was controlled with a heater con-
nected to a control unit (all Solent Scientific Limited, UK). The samples were 
excited with Polychrome IV (TILL Photonics, Germany) at a wavelength of 
488 nm. Emitted light was filtered with a Chroma filter set (EM  HQ535/50m, 
BS Q505LP, Chroma Technology Corporation, USA). Images were recorded 
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with a Hamamatsu ORCA-Flash 4.0 sCMOS camera (Hamamatsu Photonics 
K.K., Japan) at 50 – 67 frames per second. For electrical pacing, a stimulus 
isolation unit (Warner Instruments, USA) was used to give bipolar pulses of 10 
ms duration at a rate approximately 20% higher than the intrinsic beating rate 
of the cells being visualized. For control of the Polychrome light source, the 
stimulator, and the camera, HCImage software was used (Hamamatsu Photon-
ics K.K., Japan). Spontaneously beating cells to be analyzed were manually 
selected as regions of interest and the background was subtracted before quan-
tifying the fluorescence in relation to baseline fluorescence (F/F0). Ca
2+ transi-
ents were recorded at baseline conditions as well as during electrical pacing 
and/or perfusion with 1 μM isoproterenol. Again, viability of cardiomyocytes 
was confirmed after the experimental protocol.  Data acquisition and analysis 
were performed blinded to the genotype of the cardiomyocytes. Data were 
analyzed initially using the HCImage software and subsequently using Clamp-
fit (Molecular devices, USA). STV of various Ca2+ transient parameters was 
calculated from 30 consecutive transients using the formula '$`{|}|{
\"

‘D’ represents the transient rise time, decay time, duration at 
half-amplitude, amplitude, or area. Ca2+ transient alternans was defined as a 
beat-to-beat alternation of over 10% in transient amplitude between consecu-
tive even and odd transient oscillations persisting for a minimum of ten con-
secutive beats. 
2.2.5 Patch-clamp measurements 
APs were recorded in current-clamp mode with the perforated patch technique 
using Amphotericin B as the membrane perforating agent (Hamill et al. 1981). 
The extracellular solution contained 143 mmol/L NaCl, 5.0 mmol/L KCl, 1.8 
mmol/L CaCl2, 1.2 mmol/L MgCl2, 5.0 mmol/L glucose, and 10 mmol/L 
HEPES. The pH was adjusted to 7.4 with NaOH and the osmolarity to 308 ± 2 
mOsm with sucrose (Gonotec Osmomat 030, Labo Line Oy, Finland). The 
patch pipette (intracellular) solution consisted of 122 mmol/L KMeSO4, 30 
mmol/L KCl, 1.0 mmol/L MgCl2, and 10 mmol/L HEPES. The pH was set to 
7.15 with KOH and the osmolarity to 302 ± 2 mOsm. Spontaneously beating 
cardiomyocytes were patched under similar conditions as during Ca2+ imaging, 
6 – 7 days after dissociation. The patch pipettes (Harvard Apparatus, UK) 
were pulled and flame polished (Narishige, UK) to a resistance of 3.0 – 3.5 
. APs were recorded in gap-free mode using PClamp software, the signal 
was amplified with a patch-clamp amplifier, and digitized (all Molecular de-
vices, USA). The current-clamp recordings were sampled at 20 kHz and fil-
tered at 5 kHz with a low-pass Bessel filter.  
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APs were analyzed with Microcal Origin software for APD at 50% and 90% of 
repolarization (APD50 ad APD90), AP amplitude, maximum diastolic poten-
tial, and beating rate. dV/dT (V-max, maximal upslope velocity) was extracted 
from the differentiated time course traces as peak values corresponding to each 
single AP. Ventricular-like cardiomyocytes were defined by APD90/APD50 < 
1.3 and AP amplitude > 95 mV, atrial-like by APD90/APD50 > 1.3 and AP 
amplitude > 95 mV and nodal-like by APD90/APD50 > 1.3 and AP amplitude 
< 95 mV. 
 
3 Zebrafish (Study IV) 
3.1 Zebrafish husbandry 
Zebrafish embryos were maintained in a mixed population on a 14h light / 10h 
dark cycle. For experiments, we used Tu/AB wildtype (WT) lines and the in-
sertional mutant line pkd2/hi4166, which lacks expression of the PC2 protein 
(Sun et al. 2004). Embryos were collected from the tank at “dawn” after lights 
came on, and were raised at 28°C in culture medium containing 0.25 mg/L 
methylene blue in deionized water. The homozygous pkd2 mutant fish show 
dorsal body curvature, which makes them phenotypically easily distinguisha-
ble from WT/heterozygous fish, which have straight bodies. Zebrafish mainte-
nance and experiments were performed in accordance with protocols approved 
by the Institutional Animal Care and Use Committee of Yale University 
School of Medicine and conform to the NIH Guide for the Care and Use of 
Laboratory Animals. 
3.2 Immunohistochemistry  
Zebrafish embryos aged 48 – 52 hours post fertilization (hpf) were fixed over-
night and dehydrated for 24 hours. After rehydration, the embryos were 
washed and treated with trypsin-EDTA to dissociate tissues. Following three 
washes and blocking for 30 minutes, the samples were incubated in blocking 
buffer with primary antibodies for rabbit anti-zebrafish PKD2 (Obara et al. 
2006), mouse anti-BiP (BD Bioscences, USA), and mouse anti-SERCA2a 
(Pierce, USA). After numerous washes, the samples were incubated for two 
hours with fluorescence-conjugated secondary antibodies (Jackson Immu-
noResearch Laboratories, USA). Zebrafish hearts were excised manually and 
mounted on coverslips with Vectashield with DAPI (Vector Laboratories, 
USA). Images were acquired with a Nikon Eclipse upright microscope 
equipped with a Plan Apochromat 60x oil objective and NIS acquisition soft-
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ware (all Nikon Instruments, Japan). Alternatively, the samples were counter-
stained with TOTO-3 (Molecular Probes, USA) and mounted in Vectashield 
medium (Vector Laboratories, USA). Fluorescence imaging was performed on 
a LSM 710 DUO laser confocal microscope (Zeiss, Germany) using a 40x C-
Apochromat water objective and Zen 2010 software. Each fish heart was opti-
cally sectioned using a Z-	! " 
   
 -localization 
analysis and maximal Z-projections were performed in ImageJ (NIH, USA). 
3.3 Morpholino antisense oligonucleotide injections 
To silence the expression of PC2, WT eggs at the one-cell stage were injected 
with antisense morpholino oligonucleotides. MO3-pkd2 (Gene Tools, USA) 
and Phenol Red in sterile water was injected using a microinjector (World 
Precision Instruments, USA). Morphant embryos showing the typical dorsal 
body curvature at 48 hpf were selected for the immunohistochemistry experi-
ments. 
3.4 Zebrafish real time PCR 
Whole fish were used for mRNA extraction from pkd2 mutants and siblings 
with normal phenotype using microRNeasy technology (Qiagen, USA). Mul-
tiScribe reverse transcriptase (Applied Biosystems, USA) was used to obtain 
cDNA, which was then amplified in duplicate using either TaqMan (PC2 and 
SERCA2a) or SYBR Green (RyR2a, RyR2b, IP3R1, IP3R2 and IP3R3) tech-
nology on a 7500 Fast real time machine (Applied Biosystems, USA). Elonga-
tion factor 1 was used as a housekeeping gene. Data were analyzed using the 
comparative CT method (Schmittgen et al. 2008), and presented as relative 
amounts (heterozygote / pkd2 mutant). 
3.5 Zebrafish in vivo cardiac physiology 
3.5.1 Whole-fish image and heart video recordings 
WT and pkd2 mutant zebrafish embryos at 3, 6, and 9 dpf were anesthetized 
with tricaine and mounted in methylcellulose to assess for edema. Still images 
of the whole fish were captured under a dissecting microscope (Leica, Germa-
ny) using a SPOT digital camera and SPOT software (Sterling Heights, USA). 
Videos of the beating heart were captured at approximately 30 frames per sec-
ond under DIC conditions using a microscope (Zeiss, Germany) equipped with 
a confocal imager (BD Bioscience, USA), a 20x plan-apochromat air objective 
(Zeiss, Germany), and Metamorph software (Molecular Devices, USA). 
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3.5.2 Heart rate measurement 
Heart rates of embryonic zebrafish were counted during 20s intervals by di-
rectly observing ventricular contractions under a light microscope. After a 5 – 
10 minute adaptation to the light, the counting was performed three times per 
fish and the mean heart rate calculated. As the heart rates were very stable, 
"	

#

	

	?\
fish were moving actively and were therefore immobilized with low concen-
trations (75 – 125 mg/L) of tricaine that do not significantly interfere with 
heart rate (Craig et al. 2006, Denvir et al. 2008). 
3.5.3 Cardiac output measurement 
For cardiac output measurements, fish aged 742 hpf were placed into a re-
cording chamber and given 5 – 10 minutes to adapt before imaging their heart 
and blood flow in the dorsal aorta with a NeuroCCD camera (Red Shirt Imag-
ing, USA) at 125 frames per second. Due to a short recording time (4s), im-
mobilization of the fish was not necessary. The blood flow was observed in the 
dorsal aorta just above the yolk, as shown in figure 18. Flow of erythrocytes 
was tracked with the “Manual Tracking” plug-in in Image J, allowing the dis-
tance travelled by an erythrocyte during one cardiac cycle to be determined. 
 
Figure 18. A pkd2 mutant zebrafish at 3 dpf. Note the typical extensive dorsal curva-
ture. The box on the left shows the location of blood flow measurement in the dorsal 
aorta. The close-up shows measurement of aortic diameter with red arrows. The box 
on the right shows the location of the heart, in the close-up the ventricle is clearly 
visible. 
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The heart rate was counted and the aortic diameter measured and averaged 
from multiple spots along the part of aorta used to track the erythrocytes. From 
these data, cardiac output was calculated as previously reported (Bagatto et al. 
2006, Malone et al. 2007). Cardiac output (CO) = heart rate (HR) x stroke 
volume (SV), which can be calculated from the distance an erythrocyte travels 
(dx) within one cardiac cycle and the cross-sectional area of the aorta (Aaorta). 
Assuming a circular cross-section of the aorta, Aaorta = (daorta/2)
2   "


daorta is the mean diameter of the aorta. It follows that stroke volume (SV) = 
Aaorta x dx. 
3.6 Zebrafish ex vivo cardiac physiology 
3.6.1 Calcium imaging 
Under a dissection microscope, whole hearts from anesthetized zebrafish em-
bryos aged 782 hpf were excised in Tyrode's solution (136 mmol/L NaCl, 5.4 
mmol/L KCl, 0.3 mmol/L NaH2PO4, 1.8 mmol/L CaCl2, 1 mmol/L MgCl2, 5 
mmol/L glucose, 10 mmol/L HEPES, 2% BSA). The hearts were immediately 
loaded for 30 minutes with a high concentration () of the Ca2+ indi-
cator dye Fluo-4 AM (Molecular Probes, USA) together with 0.1% Pluronic F-
127 (Molecular Probes, USA), followed by a 30-minute de-esterification. Un-
harmed, spontaneously normally beating hearts were chosen for experiments. 
To eliminate motion artifacts, 15  blebbistatin was added to the imag-
ing chamber equipped with field stimulation electrodes (Warner Instruments, 
USA) (Kovács et al. 2004, Jou et al. 2010). The hearts were visualized with an 
inverted microscope (Nikon, Japan) and illuminated with a 100W lamp (Nikon, 
Japan) connected to a DC power supply (Chiu Technical Corporation, USA). 
The light was filtered with a Chroma filter set (emission HQ535/50m, excita-
tion HQ480/40x, and beamsplitter Q505LP). All stages of the experiments 
were performed at room temperature. Images were captured with a NeuroCCD 
camera at 125 frames per second (figure 19) and analyzed with Neuroplex 
Software (both Red Shirt Imaging, USA) and Clampfit (Molecular Devices, 
USA). Fluorescence was measured by manually drawing the region of interest 
separately for the atrium and the ventricle within the borders of the cardiac 
chamber in question. Background subtracted fluorescence was quantified in 
relation to baseline fluorescence (F/F0). Averaged fluorescence values from 
multiple small regions of interest within a single cardiac chamber were found 
to be similar to each other, thus a single large region of interest was used per 
cardiac chamber. The hearts were paced with bipolar pulses at 60-240 beats 
per minute (bpm) using the Neuroplex software and an external stimulus isola-
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tion unit (Warner Instruments, USA). Only hearts that were able to follow the 
pacing at the physiological rate of 140 bpm were included in the analyses. 
After the experimental protocol, viability of the hearts was confirmed by ob-
serving spontaneous beating.  
 
To investigate Ca2+ transient alternans, hearts were paced at 120 bpm for 10s.  
Ca2+ alternans was defined as a minimum difference of 10% in peak transient 
amplitude between consecutive even and odd beats that persisted for a mini-
mum of 10 consecutive beats.  
 
To measure SR Ca2+ stores, embryonic zebrafish hearts were examined ex vivo at 
483 hpf in modified Tyrode's solution lacking CaCl2 and containing 1 mmol/L 
EGTA. The hearts lacked spontaneous beating in the absence of external Ca2+. 
After 2 min of adaption, Ca2+ release from the SR stores was induced by adding 
caffeine (5 mmol/L) and thapsigargin () to the chamber. 
 
Figure 19. Fluorescent still images 
from a video of a Fluo-4 Ca2+ 
indicator loaded heart excised 
from a 2 dpf WT zebrafish. Ca2+ 
transients are imaged during spon-
taneous beating. Blebbistatin is 
used to prevent muscle contraction. 
A = atrium, V = ventricle, the AV 
junction is marked by a dotted line 
in image 1), which shows the heart 
during rest. 2) Ca2+ transient prop-
agation initiates at the top of the 
atrium, indicated by the increase in 
fluorescence intensity. 3) The 
entire atrium is activated. 4) After 
a delay at the AV junction, the 
activation spreads to the ventricle. 
5) The whole heart is now activat-
ed. 6) The atrium is quiet again, 
indicating complete decay of the 
intracellular Ca2+ transient. [Ca2+]i 
remains high in the ventricle. 7) 
Also the ventricle is returning close to resting levels of [Ca2+]i. The chart shows the 
mean fluorescence intensity plotted over time in two regions of interest, the atrium (A) 
and the ventricle (V), as shown on the last still image. Background fluorescence values 
(BG) have been subtracted from the values of traces A and V in the chart. The num-
bered arrowheads below the traces indicate the timepoints shown in the seven still 
images on the montage. 
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3.6.2 Optical action potential recordings 
APs were recorded with the same set-up that was used for Ca2+ imaging. 
Zebrafish whole hearts were excised at 4 – 6 dpf and stained with 5 μmol/L 
voltage-sensitive dye di-4-ANEPPS (Molecular Probes, USA) for 5 min and 
imaged immediately after. APD was measured from the time of maximal rise 
slope to the time at 90% repolarization. In each measurement, at least four 
consecutive APDs were averaged. Two immobilization agents, BDM and 
blebbistatin, were used at various concentrations. At the used concentrations, 
these agents had no apparent effect on the results.  
 
 
4 Statistical analysis (Studies I – IV) 
Continuous variables are shown as mean ± either standard deviation or stand-
ard error of the mean, as indicated. The significance of differences in normally 
distributed variables between two groups was calculated with the unpaired 
student’s t-test. The significance of changes within a group was evaluated with 
the paired student’s t-test. Between more than two normally distributed exper-
iments the one-way ANOVA test was used, followed by Scheffe's test. The 
Wilcoxon signed-rank and Mann-Whitney U tests were used as nonparametric 
tests. Categorical variables were assessed with the Chi-Square test. No correc-
tions were applied to account for potential inflation due to multiple testing. A 
P-	
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 Results 
1  STUDY I 
1.1 CPVT patients display DADs in MAP recordings 
In study I, we examined MAP recordings in 15 CPVT patients with RyR2 mu-
tations (nine P2328S, five V4653F, and one Q4201R) and 12 healthy subjects. 
During a bicycle exercise test, all CPVT patients showed polymorphic PVCs 
or short runs of polymorphic VT. The mean threshold heart rate for ventricular 
bigeminy was 127±20 bpm. DADs were observed in 3/15 CPVT (two P2328S 
and one Q4201R) MAPs at baseline and 4/15 (three P2328S and one Q4201R) 
during epinephrine infusion. None of the five V4653F patients showed DADs. 
On the surface ECG, DADs coincided with U-waves. Epinephrine increased 
DAD amplitude, measured normalized to the previous AP amplitude, from 6 to 
14%, and the rising slope from 6.7 to 11 mV/s. DADs occasionally triggered 
PVCs. No DADs were observed in the 12 control patients at baseline or during 
epinephrine infusion. The three CPVT patients that showed DADs already at 
baseline conditions had a significantly lower threshold for ventricular bigemi-
ny during the stress test compared to those that showed no DADs (107±21 vs. 
131±16 bpm, P<0.05). Additionally, one of these CPVT patients occasionally 
showed two- and three-peaked DADs. 
 
1.2 Cells with mutant RyR2s show increased spontaneous Ca2+ 
release under cAMP stimulation 
Expression of WT-, P2328S-, and V4653F-RyR2 in HEK 293 cells resulted in 
no significant difference in SR Ca2+ content (363±68, 299±59, and 274±33 
nM), which was measured by high-dose caffeine-induced SR Ca2+ release. 
Under unstimulated baseline conditions, spontaneous Ca2+ release events were 
very rare, with no differences between the groups. Dioctanoyl-cAMP (cAMP 
analoque with 100-fold higher activity) in three concentrations was given to 
simulate sympathetic stimulation. Spontaneous Ca2+ waves increased in a 
dose-dependent manner, occurring significantly more in cells transfected with 
mutant RyR2s. This was observed without a concomitant increase in baseline 
[Ca2+]i. 
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2 STUDY II 
2.1 Characterization of iPSC lines and cardiomyocytes 
IPSC lines were generated from a CPVT patient and from a healthy control 
subject. The presence of the RyR2-P2328S mutation was confirmed in the two 
CPVT cell lines. All cell lines were morphologically and karyotypically nor-
mal. Endogenous pluripotency genes were turned on and expressed at the pro-
tein level, and the exogenous, retrovirally encoded reprogramming factors 
were silenced. Pluripotency of cell lines was further confirmed with teratoma 
formation in vivo and expression of markers from all three germ layers in vitro. 
IPSC lines were differentiated into cardiomyocytes in a co-culture with murine 
visceral endoderm-like cells. Spontaneously beating cells expressed the cardi-
ac markers troponin T, connexin 43	-actinin at the protein level. CPVT 
and control cell lines showed similar expression levels of genes involved in 
cardiac Ca2+ cycling.  
2.2 RyR2 mutant cells show irregular Ca2+ transients 
Ca2+ imaging of spontaneously beating cells was performed. The cells were 
stimulated with electrical pacing, epinephrine perfusion, and high-dose pulses 
of caffeine. The observed Ca2+ transients were categorized into classes based 
on regularity of rhythm and transient amplitude (figure 20). In control cells, 8% 
showed irregular transients at baseline, and during epinephrine perfusion the 
proportion was 11%, although epinephrine tended to stabilize transient ampli-
tude. Pacing completely abolished irregular rhythm and transient amplitude in 
control cells. In RyR2-P2328S cells, 14% of cells showed irregular Ca2+ 
release at baseline, and this proportion was slightly attenuated during pacing 
(10%). Perfusion with epinephrine provoked irregular transients in 29% of 
cells during spontaneous beating (P<0.05 vs. baseline) and in 32% during pac-
ing.  
 
Figure 20. Repre-
sentative example of 
regular Ca2+ transi-
ents in a single car-
diomyocyte (left). 
Both frequency and 
amplitude are regular 
and stable. Repre-
sentative example of irregular Ca2+ transients in a single cardiomyocyte (right). This 
cell is arrhythmic, displaying irregular rhythm and varying amplitude of  transients.   
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2.3 Ca2+ cycling balance is altered in RyR2 mutant cells  
At baseline, diastolic [Ca2+]i levels were similar in control and RyR2-P2328S 
cells. Epinephrine raised the [Ca2+]i to significantly higher levels in RyR2-
P2328S cells than in control cells (1.20±0.11 vs. 0.84±0.03 Fura-2 ratio units, 
P=0.01). SR Ca2+ content, measured as transient amplitude of high-dose caf-
feine-induced Ca2+ release, was lower in RyR2-P2328S cells at baseline 
(1.00±0.08 vs. 1.62±0.18 Fura-2 ratio units, P=0.0003) and during pacing and 
simultaneous epinephrine perfusion (1.10±0.13 vs. 1.71±0.40 Fura-2 ratio 
units, P<0.05). Fractional Ca2+ release, referring to the amount of Ca2+ released 
from the SR during normal beating in proportion to the total SR Ca2+ store, 
was higher in RyR2-P2328S cells. This difference was clearest during pacing 
and simultaneous epinephrine perfusion, when fractional Ca2+ release in 
RyR2-P2328S cells was more than double of that in control cells (66.4±4.9% 
vs. 29.3±4.9%, P=0.000008).  
2.4 In addition to DADs, RyR2 mutant cells display EADs 
APs were measured in ventricular-like cells with the perforated patch tech-
nique. RyR2-P2328S and control cells showed similar AP morphologies. 
Three out of 16 control cells showed infrequent single DADs at baseline. No 
DADs were observed in five control cells during epinephrine perfusion. Six of 
14 RyR2-P2328S cells showed occasional DADs at baseline. In 11 RyR2-
P2328S cells exposed to epinephrine, six showed no afterdepolarizations, 
whereas five showed DADs and a subsequent decrease in beating rate. In three 
RyR2-P2328S cells that did not receive epinephrine, singular EADs were ob-
served (figure 21). All EADs were initiated above -25mV and the maximum 
EAD amplitude was 45mV. One of these cells also showed DADs and a phase 
3 burst episode lasting 20 beats. The EADs during the burst were initiated at -
50 mV and were on average 95 mV in amplitude. No EADs or burst activity 
were observed in control cells. 
 
Figure 21. Patch-clamp re-
cording of membrane potential 
(Vm) in an iPSC -derived 
RyR2-P2328S cardiomyocyte. 
Among normal APs, occasion-
al EADs were observed, as 
indicated by the arrow. 
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2.5  Changes corresponding to cellular abnormalities are observed 
in the clinical MAP and ECG recordings 
The MAP recordings reported in study I were examined for changes corre-
sponding to the findings in the iPSC-derived cardiomyocyte model. In addition 
to previously reported DADs, occasional EADs were observed in MAP record-
ings of CPVT patients, but not in MAP recordings of healthy controls. To 
avoid confusion between the second peak of a T-wave and a U-wave, 24h 
ECGs of 19 CPVT patients and 19 matched healthy controls were examined 
for the simultaneous occurrence of T1-, T2- (corresponding to EAD), and U-
waves (corresponding to DAD). Such traces were found in ECGs of only 
CPVT patients.  
 
3 STUDY III 
3.1 Isoproterenol increases variability of Ca2+ transients in RyR2 
mutant iPSC-derived cardiomyocytes 
Ca2+ transients were measured in Fluo-4 loaded spontaneously beating cells. 
RyR2-P2328S cells had shorter transient durations during baseline and isopro-
terenol perfusion. STV of the Ca2+ transient rise time, decay time, duration at 
50% amplitude, amplitude, and area were quantified from recordings of 30 
consecutive transients during baseline and perfusion with isoproterenol. Iso-
proterenol failed to significantly increase STV of any of the Ca2+ transient 
parameters in control cells, whereas in RyR2-P2328S cells there was a signifi-
cant increase in STV of Ca2+ transient duration at 50% amplitude, amplitude, 
and area, all of which approximately tripled compared to baseline values. STV 
of transient decay was similar in control and RyR2-P2328S cells, suggesting 
similar SERCA2a function. Alternans of Ca2+ transient amplitude was rare, 
occurring during isoproterenol perfusion in 3.2% of control cells and in 4.8% 
of RyR2-P2328S cells. This difference was not statistically significant. Taken 


-adrenergic stimulation induces non-alternating variability of intra-
cellular Ca2+ transients in RyR2-P2328S cells, which may affect membrane 
potential and be reflected on the surface ECG. 
 
3.2 Epinephrine decreases the rate of depolarization in RyR2 
mutant cardiomyocytes 
APs in iPSC-derived cardiomyocytes were recorded using patch-clamp. STV 
of APD50 and APD90 showed large variation between cells. Values of STV 
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APD90 were similar in control and RyR2-P2328S cells (11.0 ± 2.6 ms vs. 18.0 
± 6.4 ms, P=NS, control N=4, RyR2-P2328S N=8), and showed similar re-
sponses to epinephrine. APD90 alternans was similar, observed during epi-
nephrine in 1/4 of control and 2/8 of RyR2-P2328S cells. Epinephrine de-
creased maximal AP upslope velocity (dV/dt) (V-max) in RyR2-P2328S cells, 
whereas V-max remained unchanged in control cells (-19.6 ± 6.9% vs. +3.2 ± 
1.3%, P<0.05). 
 
3.3 Decreased rate of depolarization in response to epinephrine is 
reproduced in clinical MAP recordings of CPVT patients 
MAPs recorded from the right ventricular septum in 13 CPVT patients with a 
RyR2-P2328S mutation and four healthy controls were evaluated. For as-
sessing variability and alternans, sufficiently long MAP recordings with a sta-
ble cycling interval were available in three CPVT patients and three controls. 
STV of MAP duration (MAPD)90 was similar in control and CPVT patients at 
baseline and during epinephrine perfusion (control baseline 1.90 ± 0.37 ms, 
control epinephrine 2.99 ± 0.68 ms, CPVT baseline 2.45 ± 0.68 ms, CPVT 
epinephrine 3.22 ± 0.67 ms). MAPD alternans was observed during epineph-
rine perfusion in all three controls and in 2/3 of CPVT patients. In CPVT pa-
tients, epinephrine infusion decreased maximal MAP upslope velocity (V-
max), whereas in controls MAP V-max increased compared to baseline (-30.4 
± 11.2% vs. +31.4 ± 27.7%, P<0.05).  
 
3.4 CPVT patients show heart rate dependent changes in QT 
interval and age dependent changes in ECG R-upslope  
24h ECGs of 19 CPVT patients (13 RyR2-P2328S and six RyR2-V4653F) and 
19 age and gender-matched controls were studied. Mean 24h QT intervals 
were similar in CPVT patients and controls. CPVT patients tended to have 
shorter mean QT intervals at RR intervals 400 – 600 ms, and the difference 
reached significance at approximately half of measured timepoints, the maxi-
mal difference was 40 ms at RR interval 400ms (P<0.05). To examine whether 
the decreased rate of depolarization observed in cellular and MAP recordings 
is reflected on the surface ECG, we measured the QRS duration and deter-
mined the maximal R-spike upslope velocity (V-max). QRS durations were 
similar in controls and CPVT patients (91±11 vs. 95±14 ms, P=NS). Mean 24h 
values of R-upslope V-max were 4 – 7 mV/s lower in CPVT patients com-
pared to controls at all RR intervals 500 – 1200 ms, but this trend remained 
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statistically insignificant. Interestingly, when the subjects were divided into 
two groups based on the median age of 30, those CPVT patients older than 30 
years of age showed significantly reduced R-upslope V-max compared to 
matched controls (17 ± 2.5 mV/s vs. 28 ± 4.2 mV/s, P<0.05), as well as com-
pared to CPVT patients younger than 30 years of age (17 ± 2.5 mV/s vs. 38 ± 
3.7 mV/s, P<0.001). However, QRS durations remained similar in both age 
groups. 
 
3.5 ECGs of CPVT patients show increased non-alternating 
variability of repolarization 
Of these 19 CPVT patients, 13 had a history of exercise-related syncope or 
cardiac arrest and six were event-free. Using custom-made software, beat-to-
beat variability of repolarization was quantified for each beat as STV of the 
QT-end interval (STV QTend) and of the QT-apex interval (STV QTapex) 
from 30 preceding consecutive beats. Automated detection of the T-wave apex 
was more reliable than that of T-wave end, which occasionally merged with a 
T2- or U-wave. Compared to controls, STV QTapex values were 1.4 – 2.0 ms 
higher in CPVT patients at all RR intervals 500 – 1200 ms (plotted every 100 
ms), and this difference was significant at RR intervals 510 – 1180 ms. STV 
QTend values were 1.5 – 2.7 ms higher in CPVT patients, the difference being 
significant at 640 – 1110 ms. When CPVT patients were grouped according to 
history of arrhythmic events into symptomless, syncope, and VF/SCD groups, 
there was a trend of increasing mean STV QTapex and STV QTend with in-
creasing severity of arrhythmic symptoms. CPVT patients with a history of 
VF/SCD had higher STV QTapex than healthy controls (6.7 ± 0.7 ms vs. 4.5 ± 
0.3 ms, P<0.01). At higher heart rates, CPVT patients with a history of ar-
rhythmic events showed a trend of higher mean STV QTapex than those with-
out arrhythmic events. This difference increased from 0.6 ms at RR interval 
1200 ms to 2.9 ms at RR interval 500 ms, but remained statistically insignifi-
cant. QTVI was similar in controls and CPVT patients. 
 
3.6 CPVT patients show slightly lower alternans of repolarization 
Alternans of repolarization was determined from the same 24h ECGs with the 
MMA method and the CDM method, which is a modification of the spectral 
method. Both methods gave lower values of TWA in CPVT patients at all RR 
intervals (500 – 1200 ms), the difference to controls was significant at RR inter-
vals 510 – 680 ms (MMA) and 550 – 670 ms (CDM). The absolute differences in 
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TWA were 3.7 – 6.7 μV (MMA) and 1.7 – 4.5 μV (CDM). Neither method distin-
guished CPVT patients with a history of arrhythmic events from event-free pa-
tients at any RR interval (500 – 1200 ms). Interestingly, when CPVT patients were 
grouped according to history of arrhythmic events, an opposite trend to that in 
STV of QT was found. Mean TWA tended to decrease with increasing severity of 
arrhythmic symptoms, but the differences failed to reach statistical significance. 
UWA was lower in CPVT patients at RR intervals 500 – 600 ms with the MMA 
method and similar in controls and CPVT patients with the CDM method. Rele-
vant results in 24h ECGs are summarized in table 3. 
 
Table 3. Results of selected parameters from 24h ECGs. 
Measure Control (N=19) CPVT (N=19) P value 
  mean S.D. mean S.D.   
Mean RR interval (ms) 802 80  96 0,168 
Mean QT-end interval (ms) 393 21  28 0,896 
Mean QT-apex interval (ms) 308 20 309 22 0,919 
Mean STV QTend (ms) 5,5 1,6  2,3 0,031 
Max STV QTend (ms) 13 5,4 15 5,5 0,427 
Mean STV QTapex (ms)  1,2 5,9 2,2 0,024 
Max STV QTapex (ms)  3,5 11 4,3 0,049 
QTVI (T-end) -0,91 0,25 - 0,33 0,609 
Mean T-wave alternans (MMA) (μV) 31 8,9 25 6,2 0,020 
Max T-wave alternans (MMA) (μV)  14  8,6 0,037 
Mean T-wave alternans (CDM) (μV) 10 4,8 8,3 3,4 0,116 
Max T-wave alternans (CDM) (μV) 17 6,8  4,8 0,151 
Mean U-wave alternans (MMA) (μV) 27 6,7  6,9 0,120 
Max U-wave alternans (MMA) (μV)  9,4 37 8,5 0,153 
Mean U-wave alternans (CDM) (μV)  1,7 5,0 1,5 0,553 
Max U-wave alternans (CDM) (μV) 8,7 2,3  4,3 0,793 
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4 STUDY IV 
4.1 Polycystin-2 is expressed in the heart 
WT zebrafish express the PC2 protein throughout their hearts, where it co-
localizes with SERCA2a and Binding immunoglobulin Protein (BiP) predomi-
nantly to the SR. Pkd2 mutants lack expression of PC2, as do 2 dpf WT fish 
injected with a morholino to silence pkd2.  
4.2 Cardiac function is weakened in pkd2 mutant zebrafish 
Pkd2 mutant embryos showed lower heart rates than WT fish, and this differ-
ence increased with time. We quantified stroke volume by examining aortic 
blood flow at 3 dpf, and found significantly lower stroke volumes in pkd2 
mutant fish. The resulting cardiac output was nearly halved in pkd2 mutants 
compared to WT fish (9.8±0.7 nL/min vs. 16.7±1.1 nL/min, P<0.001). How-
ever, peak systolic velocities of erythrocytes in the proximal aorta were similar 
in WTs and pkd2 mutants (1.94±0.05 mm/s vs. 1.71±0.09 mm/s, P>0.05). 
 
The fish were observed until 9 dpf. Pkd2 mutant fish showed increasing edema 
that concentrated to the abdomen and pericardium. By 9 dpf, 77% of pkd2 
mutants showed edema. After 3 dpf, pkd2 mutant fish started developing AV 
block, where approximately 1/3 of atrial impulses failed to induce ventricular 
contraction. By 9 dpf, 28% of pkd2 mutants showed AV block. The AV block 
did not develop secondary to the edema, as some arrhythmic fish lacked edema. 
No edema or arrhythmias were observed in WT fish. Pkd2 mutants and WT 
fish had similar delays in propagation of the Ca2+ wave from atrium to ventri-
cle. Heart sizes were also similar. We did not observe significant AV valve 
defects or regurgitation.  
4.3 Pkd2 mutant zebrafish hearts display impaired Ca2+ cycling 
We performed Ca2+ imaging on Fluo-4 loaded excised whole hearts at 3 dpf. 
The duration of ventricular Ca2+ transients in pkd2 mutant fish was longer than 
in WT fish (1.40±0.19s vs. 1.03±0.09s, P<0.05). Transient rise time was dou-
bled in the ventricles (179±15ms vs. 82±15ms, P<0.001), and also transient 
decay was significantly prolonged (567±60 ms vs. 378±25ms, P<0.01). Upon 
electrical pacing at 120 bpm, pkd2 mutant hearts were prone to develop Ca2+ 
transient amplitude alternans. 15% of pkd2 mutant hearts had alternans, 
whereas no alternans was observed in WT hearts. In pkd2 mutant ventricles, 
pacing increased diastolic Ca2+ levels in the cytosol (+74±20%, P<0.01 vs. 
79 
 
Results 
 
baseline), whereas in WT ventricles diastolic Ca2+ levels were unchanged by 
pacing (+22±10%, P>0.05 vs. baseline). These responses to pacing were sig-
nificantly different between pkd2 mutant and WT fish (P<0.05). Also ventricu-
lar SR Ca2+ stores, measured as transient amplitude of caffeine-induced Ca2+ 
release, were found to be reduced in pkd2 mutants compared to WT fish (F/F0: 
2.47±0.54 vs. 4.42±0.91, P<0.05). Quantitative reverse transcription PCR was 
performed to quantify mRNA levels of Ca2+ cycling proteins that might ex-
plain the observed functional differences between pkd2 mutants and WT fish. 
We found no differences in the mRNA levels of RyR2a, RyR2b, SERCA2a, 
IP3R1, IP3R2, and IP3R3 that are likely to explain the functional differences. 
The results indicate that PC2 is necessary for normal Ca2+ cycling in the heart. 
4.4 Ventricular APD is shortened in pkd2 mutants 
Optical AP measurements were performed in di-4-ANEPPS loaded excised 
whole hearts of 4 – 6 dpf fish. Compared to WT fish, pkd2 mutants showed 
shorter APD during spontaneous beating (in ms: 272±8 vs. 233±8, P<0.01) 
and consistently during all frequencies of pacing, faster AV conduction (in ms: 
83±4 vs. 65±4, P<0.01), and capture at a higher maximum frequency of pacing 
(in bpm: 161±12 vs. 207±3, P<0.01).  
4.5 Prevalence of dilated cardiomyopathy is high in ADPKD 
patients  
We examined the Mayo ADPKD Mutation Database for an association be-
tween ADPKD and IDCM. We focused on genotyped ADPKD patients with 
known PKD mutations. Of the 307 PKD1 patients, seven patients from seven 
different families had a diagnosis of IDCM. There were 67 PKD2 patients, of 
whom six patients from four families had a diagnosis of IDCM. All PKD2 
mutations in these four families are predicted to lead to truncation of the PC2 
protein. Additionally, two other PKD2 patients from the same families had 
subclinical or stress-induced DCM. One family member had a diagnosis of 
IDCM in the absence of ADPKD. Of the six PKD2 IDCM patients, at the time 
of IDCM diagnosis four were normotensive, five had serum creatinine values 
80 – 115 μmol/L indicating preserved kidney function, four had conduction 
abnormalities, and five had ventricular extrasystoles. One patient received a 
heart transplant due to IDCM. Among these six patients, the mean age at diag-
nosis was 52 for ADPKD, 56 for IDCM , and 60 for hypertension. 
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1 Main findings 
In study I we recorded right ventricular MAPs in CPVT patients carrying 
RyR2 mutations, and in control subjects. CPVT patients displayed DADs that 
increased in magnitude in response to epinephrine infusion. These DADs were 
reflected as U-waves on the surface ECG, and occasionally triggered APs and 
PVCs. No DADs were observed in MAP recordings of control patients. Intra-
cellular Ca2+ handling was studied in HEK cells, which had been transfected 
with WT or mutant RyR2s. No spontaneous Ca2+ release events were observed 
under baseline conditions. Sympathetic stimulation, which was mimicked by 
bathing the cells in a cAMP-analoque, resulted in increased spontaneous Ca2+ 
release events in cells expressing mutant RyR2s compared to cells expressing 
WT RyR2.  
 
In study II we generated iPSC lines from skin fibroblasts of a CPVT patient 
carrying a RyR2-P2328S mutation, and from a healthy control. We then inves-
tigated cellular electrophysiology and intracellular Ca2+ handling in cardiomy-
ocytes differentiated from these iPSC lines. In patch-clamp studies RyR2-
P2328S cells exhibited DADs, as well as EADs. Corresponding changes were 
present in clinical MAP recordings of CPVT patients. Control cells displayed 
rare single DADs and no EADs. No EADs or DADs were observed in MAP 
recordings of control subjects. At baseline Ca2+ transients were similar in WT 
and RyR2-P2328S cells. Stimulation with epinephrine increased irregularity of 
rhythm and amplitude of Ca2+ transients in RyR2-P2328S cells, and resulted in 
elevation of diastolic [Ca2+]i. SR Ca
2+ stores were lower in RyR2-P2328S cells, 
and the proportion of SR Ca2+ released per beat was higher in RyR2-P2328S 
cells, most notably during pacing under epinephrine perfusion. 
 
In study III we quantified the variability of Ca2+ release by calculating STV of 
Ca2+ transients in iPSC-derived cardiomyocytes, using the same cell lines as in 
study II. Ca2+ transients were measured during baseline and isoproterenol per-
fusion. -agonists increased STV of Ca2+ transients in RyR2-P2328S. In patch-
clamp 
	

-agonists decreased the rate of depolarization in RyR2-
P2328S cells, but not in control cells. Clinical MAP recordings reproduced the 
depolarization changes observed in the cell model, with decreased rates of 

		  

 -agonists only in CPVT patients. In 24h ECG 
recordings of CPVT patients and matched controls, the rate of depolarization 
was evaluated by examining maximal R-upslope velocity. CPVT patients had 
a trend toward lower maximal R-upslope velocity, which failed to reach statis-
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tical significance. However, the maximal R-upslope velocity decreased nota-
bly in older CPVT patients compared to young CPVT patients and to age-
matched controls. To assess variability in 24h ECGs, STV of the QT interval 
was calculated. STV of QT was higher in CPVT patients compared to controls, 
and highest in those CPVT patients that had a history of severe arrhythmic 
symptoms. In contrast, TWA was higher in control subjects than in CPVT 
patients. The difference in TWA was clearest at high heart rates.  
 
Based on the findings in studies I – III, various potential arrhythmia mecha-
nisms of CPVT were identified. They are summarized in figure 22. 
Figure 22. Discovered potential arrhythmia mechanisms of CPVT. The ‘?’ refers to a 
hypothecial anatomical substrate, for example fibrosis, which needs to be investigared 
further. 
 
In study IV, cardiac function was investigated in a zebrafish model of PKD 
that lacks expression of the PC2 protein. In vivo studies revealed reduced car-
diac output, edema, and arrhythmias in the pkd2 mutant fish, indicating heart 
failure. Ex vivo Ca2+ imaging of zebrafish hearts showed impaired Ca2+ cycling 
in the pkd2 mutant fish, characterized by slow transients, Ca2+ alternans, and 
poor tolerance when stressed with pacing. Examination of the Mayo ADPKD 
Mutation Database for an association between ADPKD and IDCM showed 
that IDCM is common among ADPKD patients, especially those patients with 
PKD2 mutations.  
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2 Relation to previous studies 
2.1 Study I 
Study I was the first to show DADs in CPVT patients with RyR2 mutations. A 
case report published a decade earlier, when the genetic background of CPVT 
was unknown, showed similar findings in a 14-year-old male (Nakajima et al. 
1997). In our study CPVT patients displayed DADs with concomitant U-
waves and occasional PVCs. Cells expressing two mutant RyR2s showed 
spontaneous Ca2+ release events during low-dose cAMP stimulation. Our re-
sults suggest mutant RyR2s induce DADs and triggered activity by spontane-
ous SR Ca2+ release under conditions of sympathetic stimulation. In unstimu-
lated baseline conditions, spontaneous Ca2+ release events were rare. This dif-
fers from a previous report where a gain-of-function mutation in RyR2 led to 
frequent spontaneous Ca2+ waves (Jiang et al. 2002b). This contrasting result 
may be due to differences in experimental protocol, e.g. expression levels of 
transfected RyR2 channels, or sensitivity and duration of Ca2+ imaging. Alter-
natively, the result might be explained by a mutation-specific difference in 
basal Ca2+ activity. Diastolic [Ca2+]i levels remained essentially constant dur-
ing cAMP stimulation, indicating that [Ca2+]i alone is unlikely to account for 
the increase in spontaneous Ca2+ release. Our results suggest that the increased 
propensity to Ca2+ waves in the RyR2 mutants is explained by lowering of the 
Ca2+ release threshold due to increased sensitivity to cytosolic or luminal (SR) 
Ca2+. 
 
Marks and colleaques have found that the RyR2-calstabin2 interaction is a 
mechanistically important regulator of RyR2 Ca2+ release (Lehnart et al. 2004b, 
Wehrens et al. 2005). Interestingly, the same three RyR2 mutations as in our 
study (P2328S, V4653F, and Q4201R) showed decreased calstabin2 binding 
and the experimental drug JTV519 normalized RyR2 channel function by 
binding calstabin2 to RyR2 (Lehnart et al. 2004a). We transfected HEK293 
cells with mutant and WT RyR2, but not with calstabin2. These cells lack ex-
pression of calstabin2 (Gaburjakova et al. 2001, Zissimopoulos et al. 2005, 
Xiao et al. 2007). Thus, in our model the increased propensity of mutant RyR2 
for spontaneous Ca2+ release was independent of calstabin2. While we did not 
study the role of calstabin2, many others have addressed these questions. 
Compared to WT RyR2, several RyR2 mutants showed similar or increased 
binding to calstabin2 under baseline and oxidized conditions (Zissimopoulos et 
al. 2009). In separate work, -adrenergic induced hyperphosphorylation of 
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RyR2 led to increased SR Ca2+ release in cells with mutant RyR2, despite 
equivalent dissociation of calstabin2 from RyR2 as in cells with WT RyR2 
(George et al. 2003). Furthermore, stimulation with caffeine, which also in-
creased Ca2+ release in cells with mutant RyR2, had no effect on the extent of 
the RyR2-calstabin2 interaction. The authors concluded that altered regulation 
of RyR2 by calstabin2 is unlikely to explain the functional defect in mutant 
RyR2. Studies using various models have given contrasting results. Thus the 
role of calstabin2 in RyR2 Ca2+ release remains incompletely understood. 
 
Because the MAP catheter records electrical activity from a region of a few 
millimeters in its vicinity, our MAP recording from a single site per patient 
will likely have missed the majority of DADs generated further away in the 
ventricles (Franz 1999). This is likely to explain the lack of an increase in 
DAD amplitude associated with a premature ventricular beat. DADs were 
observed in three CPVT patients consistently even at baseline. The magnitude 
of DADs increased with epinephrine stimulation, increasing the likelihood for 
reaching threshold voltage for triggering ectopic beats. This is supported by 
the finding that patients who showed DADs at baseline developed ventricular 
extrasystoles at a significantly lower heart rate than those with no DADs at 
baseline. Under conditions of Ca2+ overload, polymorphic VT may be caused 
by DAD-mediated triggered activity arising from multiple locations in the 
ventricles (Katra et al. 2005). Although frequent DAD-mediated triggered 
activity may explain slow PVT, its degeneration to hemodynamically unstable 
rapid VT and VF is likely to involve additional mechanisms. Epicardial myo-
cytes are the last to depolarize but the first to repolarize. Therefore, triggered 
beats in the epicardium most clearly increase spatial heterogeneity of repolari-
zation, forming a functional substrate that predisposes to conduction block and 
reentry, which underlie the transition from slow to rapid VT that may degener-
ate further into VF (Nam et al. 2005). 
 
2.2 Study II 
The recent discovery of iPSCs derived from human adult somatic cells, and 
their differentiation into cardiomyocytes in vitro, has opened novel possibili-
ties to investigate the mechanisms of CPVT in a patient-specific manner. This 
avenue has been enthusiastically pursued, as evidenced by the flood of reports 
using iPSCs to model CPVT in recent years (Fatima et al. 2011, Itzhaki et al. 
2012, Jung et al. 2012, Novak et al. 2012, Di Pasquale et al. 2013, Zhang et al. 
2013a). 
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The strength of study II is the identification of EADs as a novel manifestation 
in CPVT. Furthermore, the results of Ca2+ imaging experiments suggest Ca2+-
mediated mechanisms behind the EAD-formation. Importantly, corresponding 
changes in electrical instability are also manifested in clinical MAP and ECG 
recordings. 
 
As discussed above, diastolic release of Ca2+ from the SR underlies DADs, 
which may generate triggered arrhythmias (Schlotthauer et al. 2000). We ob-
served disturbances in intracellular Ca2+ release in RyR2-P2328S cells upon 
stimulation with epinephrine, correlating with the clinical manifestation of 
arrhythmias under conditions of physical or mental stress. Epinephrine perfu-
sion transferred the balance of Ca2+ cycling more toward Ca2+ release, as indi-
cated by increased diastolic [Ca2+]i, decreased SR Ca
2+ content, and increased 
fractional Ca2+ release. It must be acknowledged that the measurement of dias-
tolic [Ca2+]i is technically challenging, therefore these results between different 
cells have to be interpreted with caution. Overall, our results demonstrate in-
creased sensitivity of Ca2+ release in mutant RyR2. This finding is essential in 
explaining the phenotypic changes observed in CPVT.  
 
The long established view was that EADs develop under conditions of APD 
prolongation, such as LQT2, when the LTCCs have sufficient time to recover 
from inactivation and reactivate while the membrane is still depolarized 
enough (January et al. 1992). However, recent findings highlight the roles of 
cytoplasmic Ca2+ overload and spontaneous Ca2+ release in EAD formation 
(Volders et al. 2000, Xie et al. 2009). The result of this “excess” Ca2+ in the 
cytosol is the activation of NCX, resulting in inward currents manifesting as 
afterdepolarizations. Viewed in this light, the mechanistic distinction between 
EADs and DADs is not necessarily great. Thus, the observation of EADs in 
RyR2-P2328S cells, though novel, cannot be considered surprising. Indeed, 
previous findings in ECG recordings of CPVT patients suggested the possibil-
ity of EAD-mediated triggered activity (Viitasalo et al. 2008).  
 
Overall, the iPSC-derived cardiomyocyte model of CPVT recapitulated the 
arrhythmic changes observed clinically. This confirms the usefulness of the 
model in pathomechanistic studies, and suggests its applicability to screening 
and optimization of drugs. 
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2.3 Study III 
In the third study we investigated depolarization, and repolarization variability 
and alternans in CPVT using in vivo and in vitro methods. IPSC-derived RyR2 
mutant cardiomyocytes showed increased variability of Ca2+ 	
-
agonist stimulation. Results of clinical MAP recordings were in line with the 
in vitro findings. Importantly, these results were consistent in 24h ECGs, 
which showed increased variability of the QT interval but decreased repolari-
zation alternans in CPVT patients.  
 
STV of APD failed to distinguish iPSC-derived CPVT cardiomyocytes from 
control cardiomyocytes. Similarly, STV of MAPD failed to distinguish CPVT 
patients from healthy controls. Nevertheless, there was a consistent trend of 
higher STV of APD and MAPD in CPVT cardiomyocytes and patients com-
pared to controls. However, the small number of cells and patients precludes 
drawing definite conclusions based on these data alone.  
 
As was reported in study II, during epinephrine perfusion irregular Ca2+ transi-
ents were observed in approximately 29% of RyR2 mutant cells and 11% of 
control cells. On the other hand, Ca2+ transient amplitude alternans was com-
paratively rare, observed in less than 5% of cells during epinephrine perfusion. 
Based on the findings of abundant irregular non-alternating Ca2+ release in the 
cell model of CPVT, we hypothesized that this variability might be reflected 
on the ECG in CPVT patients. Beat-to-beat variability measured over periods 
of 30 beats was chosen to quantify such variability. STV measures rapid 
changes, occurring from one beat to another, whereas QTVI measures slower 
changes that do not consider the beat-to-beat order of these changes 
(Oosterhoff et al. 2011). STV QTapex and STV QTend were high in CPVT 
patients, whereas QTVI was similar to control patients, suggesting that the 
changes in QTapex and QTend in CPVT patients are rapid irregular events. 
This is in line with the changes observed in the cell model. Consistently, tran-
sient QT prolongation after rapid pacing has been associated with arrhythmia 
induction in CPVT patients (Nof et al. 2011). 
 
To our knowledge, non-alternating beat-to-beat variability of repolarization is 
previously uninvestigated in CPVT patients. It has recently been linked to 
ventricular arrhythmia in patients with LTQ2 (Nemec et al. 2010) and in a 
mouse model lacking CASQ2 (Mezu et al. 2012). These studies suggest aber-
rant intracellular Ca2+ handling as a central pathomechanism, indicating poten-
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tial mechanistic similarities with RyR2 mutations (Antoons et al. 2010, Brette 
2010). Additionally, mice harboring RyR2 mutations showed increased non-
alternating variability of Ca2+ transients at the organ level (ex vivo) in response 
to adrenergic stimulation (Chen et al. 2012). This was associated with corre-
sponding changes in AP morphology. More supportive evidence comes from a 
recent study that found increased isoproterenol-induced spontaneous Ca2+ re-
lease by RyR2s to underlie increased beat-to-beat variability of repolarization 
that could be rescued by inhibiting spontaneous SR Ca2+ release (Johnson et al. 
2013). These changes were independent of APD. Likewise, a study in DCM 
patients with moderate heart failure found STV of the QT interval to be higher 
than in controls, and to be the strongest indicator of a history of VT, independ-
ent of QT interval prolongation (Hinterseer et al. 2010). Indeed, such non-
alternating variability or repolarization may reflect different underlying phe-
nomena than TWA. For example, beat-to-beat variability of repolarization 
increased, but TWA remained negative in a pig model of myocardial infarction 
(Flore et al. 2011). Pacing induced TWA similarly in pigs with myocardial 
infarction and sham pigs, whereas VF was inducible in 25% of pigs with myo-
cardial infarction and none of the sham-operated pigs. 
 
In the past decade, microvolt TWA has been studied in numerous patient 
groups. Although TWA on the surface ECG has been found to predict ventric-
ular arrhythmias, consensus on its clinical applicability remains unestablished 
(Calo et al. 2011, Gupta et al. 2012). Until now TWA remains poorly investi-
gated in CPVT patients. One study found UWA in one CPVT patient follow-
ing rapid pacing, and in another following an exercise stress test (Aizawa et al. 
2006). Murine hearts hetero- and homozygous for the RyR2-P2328S mutation 
were evaluated ex vivo for MAPD alternans during rapid pacing and epineph-
rine (Sabir et al. 2010). The authors saw higher MAPD alternans in homozy-
gous mice during epinephrine infusion and pacing at short cycling intervals, 
and conclude that their findings confirm an alternans phenotype in the RyR2-
P2328S murine heart. However, it remains unclear why the group with the 
highest proportion of observed arrhythmias was WT mouse hearts receiving 
epinephrine + propranolol or why in homozygous RyR2-P2328S mouse hearts 
receiving propranolol, the epinephrine stress test increased observed arrhyth-
mias, but approximately halved the alternans magnitude at the fastest cycling 
interval. The conclusion reached by the authors contradicts our findings. In 
addition to interpretation of data, this opposing result may be explained by 
differences in pacing and drug protocols, and by differences between mice and 
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humans, exemplified by heart rates that in mice are 6-fold compared to hu-
mans. 
 
At slow and moderate heart rates TWA was similar in CPVT patients and con-
trols. At higher heart rates, TWA was higher in controls, measured with both 
MMA and CDM methods. This may be related to shortened and reduced re-
fractoriness of mutant RyR2s (Györke 2009). Alternans is caused by an imbal-
ance in Ca2+ cycling, due to abnormal release and/or reuptake of Ca2+ (Laurita 
et al. 2008a). Gain-of-function mutations in RyR2, the main Ca2+ release 
channel, may thus enable faster cycling of Ca2+ and decrease the likelihood of 
developing alternans. Most available evidence supports this hypothesis. Drugs 
that render the SR leaky by increasing RyR2 open probability decrease alter-
nans in normal and failing rat hearts (Dumitrescu et al. 2002). In rat ventricular 
myocytes, decreasing RyR2 open probability promotes the development of 
alternans (Diaz et al. 2002). This is associated with prolongation of Ca2+ tran-
sient rise and decay times. Consistent with this finding, compared to control 
cells we saw significantly faster rise and decay times of Ca2+ transients in 
RyR2 mutant cells. In line with this, mice lacking CASQ2 show faster Ca2+ 
transient rise times, shortened RyR2 refractoriness, reduced Ca2+ alternans, 
and lower TWA (Kornyeyev et al. 2012). Also modeling studies find a causal 
relationship between increased RyR2 refractoriness and Ca2+ alternans 
(Alvarez-Lacalle et al. 2013). Furthermore, upon rapid pacing, canine transmu-
ral ventricular wedge preparations show spontaneous Ca2+ release and DADs 
most often endocardially, but the observed Ca2+ alternans does not correlate 
with these sites of spontaneous Ca2+ release (Katra et al. 2005). However, also 
contrasting findings have been reported. Calstabin2-deficient mice showed 
MAP alternans that closely associated with bidirectional VT, suggesting that 
both increased and decreased RyR2 activity may result in alternans (Lehnart et 
al. 2006). In addition to the findings discussed above, the lower TWA ob-
served in the CPVT patients at high heart rates may be explained by interfer-
ence to the alternating pattern by increased non-alternating beat-to-beat varia-
bility of repolarization, which might have reduced the occurrence and/or de-
creased the magnitude of alternans. 
 
Upon examining depolarization, we found that stimulation with epinephrine 
decreased AP upslope velocity (V-max) significantly in RyR2 mutant cells and 
MAP recordings of CPVT patients, whereas in control cells and patients V-
max remained unchanged. A similar finding was recently reported in homozy-
gous RyR2-P2328S mouse hearts (Zhang et al. 2013b). Additionally, the au-
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thors found decreased epicardial conduction velocity that associated with ar-
rhythmia. QRS duration was similar in control and RyR2 mutant mice at base-
line and in response to isoproterenol+caffeine. This is consistent with our find-
ing of similar QRS durations in controls and CPVT patients.   
 
We found the reduction of V-max in single mutant RyR2 cells in response to 
epinephrine to be relatively smaller than that observed in the clinical MAP 
recordings. As the MAP catheter records activity from a region of a few mil-
limeters, this greater reduction in V-max may be due to decreased conduction 
velocity within the recording area. At the cellular level V-max is decreased by 
the inhibitory effect of high [Ca2+]i on INa (Casini et al. 2009). In study II, we 
found higher [Ca2+]i in RyR2 mutant cells during adrenaline perfusion, sug-
gesting this may have contributed to the observed decrease in V-max at the 
level of the single cardiomyocyte, and perhaps also indirectly to conduction 
between cells. However, because we did not measure INa directly, only cau-
tious interpretations can be made based on these results alone. Additionally, 
high [Ca2+]i is known to promote closure of gap juctions and thus impair cell-
to-cell conduction (Kurebayashi et al. 2008). Importantly, the authors found 
that this propagation delay caused beat-to-beat variability in conduction and 
Ca2+ transients. Therefore it is reasonable to hypothesize that conduction delay 
under conditions of high [Ca2+]i may provide an arrhythmogenic substrate for 
block and reentry in CPVT, possibly contributing to degeneration of slow VT 
to rapid VT and VF. 
 
On the ECG, R-upslope V-max was similar in controls and CPVT patients, 
though the trend toward lower R-upslope V-max in CPVT patients is con-
sistent with the findings of decreased AP and MAP upslope V-max observed 
in CPVT cells and patients, respectively. Interestingly, there was a marked 
reduction in R-upslope V-max in older CPVT patients, suggesting potential 
disease progression. Such reduction in conduction velocity may involve fibro-
sis following the death of cardiomyocytes. As discussed, intracellular Ca2+ 
overload can lead to cell death and fibrosis. In addition to the high [Ca2+]i ob-
served in vitro in CPVT cardiomyocytes, the shortened QT interval observed 
in CPVT patients at high heart rates is a finding indirectly suggesting the pos-
sibility of  high [Ca2+]i in vivo. High [Ca2+]i may lead to shortened QT interval 
by more rapid LTCC inactivation resulting in shortening of APD. Furthermore, 
leaky RyR2s are also known to contribute to myocardial remodelling and fi-
brosis (Fauconnier et al. 2011, Sedej et al. 2013). Additionally, the lack of 
CASQ2, which leads to a CPVT phenotype, has recently been associated with 
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increased fibrosis (Glukhov et al. 2013). Such fibrosis may increase the likeli-
hood of sustained arrhythmias by forming an anatomical substrate for reentry.  
2.4 Study IV 
In study IV, the focus on the role of Ca2+ is shifted from arrhythmias to heart 
failure. Using a zebrafish model lacking the PC2 protein, we described weak-
ened cardiac function and showed underlying impairment in intracellular Ca2+ 
cycling. The clinical significance of these findings is supported by the high 
prevalence of IDCM among patients with PKD2 mutations.  
 
Young normotensive ADPKD patients with preserved renal function show 
diastolic ventricular dysfunction (Oflaz et al. 2005). Our findings are in 
agreement with this, as most PKD2 patients had normal blood pressure and 
kidney function at the time of IDCM diagnosis. Diastolic dysfunction was also 
hypothesized as a possible mechanism behind heart failure in pkd2 knockout 
mice, which die before parturition (Wu et al. 2000). Altered Ca2+ handling is 
implicated in diastolic dysfunction, which is characterized by reduced cardiac 
output and prolonged relaxation (Periasamy et al. 2008). Several findings in 
the zebrafish model indicate a predominantly diastolic mechanism of heart 
failure. Peak systolic flow velocity in the aorta was maintained in pkd2 mutant 
fish, although cardiac output was almost halved compared to WT fish. The 
prolongation of ventricular Ca2+ transients in the pkd2 mutants was mainly due 
to slow transient decay (approximately +200 ms in pkd2 mutants), i.e. slow 
relaxation. Furthermore, preservation of normal heart size, but poor ability to 
cycle Ca2+ when stressed with pacing, point towards diastolic dysfunction in 
the pkd2 mutant fish (Chatterjee et al. 2007). 
 
Defects in intracellular Ca2+ handling are known to underlie development of 
DCM. Impaired reuptake of cytosolic Ca2+ to the SR and therefore prolonga-
tion of Ca2+ transient decay have been shown to cause DCM and heart failure 
(Schmitt et al. 2003). Also abnormal release of Ca2+ from the SR is implicated 
in DCM. RyR2 mutations that reduce the threshold concentration of luminal 
SR Ca2+ at which RyR2 terminates Ca2+ release, are associated with increased 
fractional Ca2+ release and DCM (Tang et al. 2012). Interestingly, RyR2 muta-
tions that increase the threshold concentration of luminal SR Ca2+ release ter-
mination and reduce fractional Ca2+ release associate with hypertrophic cardi-
omyopathy and not DCM. Previous findings in murine cardiomyocytes have 
shown that PC2 binds to RyR2, keeping it closed during diastole (Anyatonwu 
et al. 2007). We suggest that loss of PC2 function may lead to prolonged RyR2 
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openings and promote the development of DCM in a similar manner. Support-
ing this hypothesis are the prolonged Ca2+ transients, increased diastolic [Ca2+]i, 
and decreased SR Ca2+ stores observed in the pkd2 mutant hearts. 
 
We observed occasional Ca2+ transient amplitude alternans in pkd2 mutant 
hearts. Ca2+ alternans manifests on the ECG as TWA, which is a common 
finding in patients with IDCM and heart failure, and a known predictor of 
SCD due to ventricular tachyarrhythmias (Pruvot et al. 2004, Narayan 2006, 
Salerno-Uriarte et al. 2007). Ca2+ alternans is caused by an imbalance in Ca2+ 
cycling due to abnormal release or reuptake of Ca2+ (Laurita et al. 2008a). 
Abnormal RyR2 function can cause Ca2+ alternans. As discussed above, most 
evidence implicates depressed RyR2 activity with Ca2+ alternans (Diaz et al. 
2002, Pieske et al. 2002, Kornyeyev et al. 2012, Alvarez-Lacalle et al. 2013), 
but also increased RyR2 activity might cause it (Lehnart et al. 2006). It is 
therefore possible that increased RyR2 activity due to loss of inhibition by 
PC2 might lead to Ca2+ alternans. However, PC2 is known to interact with 
multiple proteins involved in intracellular Ca2+ cycling, as reviewed above. 
These interactions require further studies to pinpoint the exact molecular 
mechanisms of the discovered cardiac dysfunction.  
 
The pkd2 mutant hearts showed regular prolonged Ca2+ transients. Despite 
elevated diastolic [Ca2+]i levels, no spontaneous diastolic Ca
2+ release events 
were observed. Similarly, triggered beats and even afterdepolarizations were 
absent in the optical AP measurements. This indicates NCX activity remained 
below threshold for detecting observable diastolic inward currents 
(Langenbacher et al. 2005). This is expected, because in zebrafish SR Ca2+ 
release contributes to contraction less than in mammals, thus making aftertran-
sients and DADs less likely (Xie et al. 2008b, Zhang et al. 2011). ICa,L through 
LTCCs contributes importantly to APD (Brette et al. 2008, Nemtsas et al. 2010) 
and [Ca2+]i-dependent inactivation of LTCCs is an important regulator of APD 
in zebrafish hearts (Zhang et al. 2011). The relative contribution of LTCC and 
NCX to APD is species-specific. In zebrafish and other species with long APD, 
an increase in [Ca2+]i will decrease APD by faster inactivation of LTCCs (Han 
et al. 2002). Therefore, faster inactivation of LTCCs due to high [Ca2+]i may 
explain the shorter APD and capture at faster rates of pacing observed in the 
pkd2 mutant ventricles. However, additional sarcolemmal Ca2+ currents may 
have contributed to the observed difference in APD between pkd2 mutant and 
WT fish. 
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Two out of six PKD2 IDCM patients and approximately 28% of pkd2 mutant 
fish had AV block. Prolonged Ca2+ transients in the pkd2 mutant hearts lower 
the maximum frequency with which they are able to cycle Ca2+ and maintain a 
normal contraction-relaxation cycle. As a critical threshold rate is reached, the 
ventricle fails to contract. This is preceded by the development of Ca2+ alter-
nans as an indication of the Ca2+ cycling capacity nearing its limits, as ob-
served in the pkd2 mutant hearts already at a physiological rate of pacing (120 
bpm). Additionally, faster AV conduction in pkd2 mutant hearts may have 
contributed to the occasional inability of the atrial AP to induce ventricular 
contraction, as the arriving impulse may have met a ventricular Ca2+ cycling 
machinery that was still refractory. On the other hand, faster AV conduction 
may in part have decreased cardiac output in pkd2 mutants by reducing the 
time available for ventricular filling. 
 
In the Mayo ADPKD Mutation Database, approximately 9% of genotyped 
PKD2 patients had a diagnosis of IDCM. Additionally two PKD2 patients had 
subclinical or stress-induced DCM. In genotyped PKD1 patients, the preva-
lence of IDCM was approximately 2%. PC2 forms a Ca2+ channel and inter-
acts with multiple Ca2+ cycling proteins, whereas PC1 interacts closely with 
PC2 (Casuscelli et al. 2009). In this light the result of increased IDCM preva-
lence in PKD patients is logical, with PKD2 patients being more often affected 
than PKD1 patients. The association between ADPKD and IDCM seems true, 
as the prevalence of IDCM among ADPKD patients is 86-fold higher than 
among the general population. However, examining patients in the ADPKD 
Mutation Database probably introduces a bias, as symptomatic patients with a 
more severe disease phenotype are more likely to be included in the analysis 
and to undergo thorough cardiac evaluation. On the other hand, this bias 
should favor inclusion of PKD1 patients, who develop symptoms and progress 
to end-stage renal disease earlier than PKD2 patients. It is therefore interesting 
to note that of the 11 families with identified PKD mutations, four (36%) had 
PKD2 mutations. This is a higher proportion than the 10 – 15% usually identi-
fied in clinical studies, where PKD2 patients may be under-represented due to 
a milder disease phenotype (Rossetti 2007). It is therefore also possible that 
cases of early or mild IDCM may have gone undiagnosed, especially in PKD2 
patients with a mild kidney disease phenotype. Still, ADPKD does not fully 
explain the cases of IDCM in these families, as one family member had IDCM 
but no PKD mutations or clinical PKD. We hypothesize that ADPKD increas-
es the risk of developing cardiomyopathy, and requires additional genetic or 
environmental factors to cause symptomatic disease. 
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In summary, in study IV we found a novel association between ADPKD and 
IDCM. Based on the zebrafish model lacking PC2 we suggest impaired Ca2+ 
cycling as a potential mechanism leading to prolonged Ca2+ transients, elevat-
ed diastolic [Ca2+]i, Ca
2+ alternans, AV block, and reduced cardiac output due 
to mainly diastolic dysfunction. While many questions about the molecular 
pathomechanisms and the nature of the relationship between ADPKD and 
IDCM remain, we recommend considering ADPKD as a disease that may 
predispose to IDCM. 
 
3 Study limitations 
3.1 Monophasic action potential recordings 
The dose of epinephrine infused during MAP recording was low, resulting in 
an average heart rate of 87 bpm in CPVT patients and 90 bpm in control sub-
jects. These heart rates are well below the threshold for development of ven-
tricular arrhythmias, partly explaining why most CPVT patients failed to show 
DADs. MAPs were recorded at a single endocardial site in the right ventricular 
septum. As the MAP catheter records electrical area only from its vicinity, the 
ventricular extrasystoles coinciding with DADs of low amplitude may have 
been initiated at sites further in the ventricles. Furthermore, MAPs record ex-
tracellular activity, and therefore provide only limited information on events 
taking place across the cell membranes.  
3.2 Studies in HEK 293 cells 
HEK 293 cells are morphologically different from cardiomyocytes. In cardio-
myocytes, RyR2s are located on the SR membrane in the immediate proximity 
of T-tubules, whereas HEK 293 cells lack T-tubules. Ca2+ release events in 
HEK 293 cells are notably slower than in cardiomyocytes, indicative of under-
lying differences in the Ca2+ cycling machinery. Cardiomyocytes might there-
fore provide a more optimal model for functional studies. 
3.3 ECG recordings 
Noise and acquisition frequency of the ECG signal are limiting factors in the 
24h recordings. Although noisy signal is excluded using automated and manu-
al methods, signal qualities between and within recordings remain variable to 
some extent. The data acquisition frequency of 128Hz limits the accurate anal-
ysis of changes especially of short intervals/segments such as QRS duration, 
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when using raw unsampled data. Higher data acquisition frequency and im-
provement of signal-to-noise ratio will increase the accuracy of ECG analyses. 
3.4 Studies in iPSC-derived cardiomyocytes 
The studies were limited to studying two cell lines generated from a single 
CPVT patient, and two cell lines from a single healthy control. We cannot 
therefore conclude whether the changes we saw are specific to this mutation, 
this patient, or even only these cell lines. Future studies will need to examine 
identical and different mutations in multiple cell lines derived from multiple 
patients. A weakness of the Ca2+ imaging method is not being able to distin-
guish between the varipus types of cardiomyocytes (atrial, nodal, or ventricu-
lar). Therefore, although based on patch-clamp experiments the vast majority 
of beating cells are ventricular-like cardiomyocytes, also other cardiomyocyte-
types may have been included in the Ca2+ imaging studies. One solution to this 
problem will be to measure APs and Ca2+ transients simultaneously. Im-
portantly, simultaneous recording will give important mechanistic information 
on the interplay between Ca2+ cycling and membrane potential. Another weak-
ness of this novel model is the immature phenotype of the differentiated cardi-
omyocytes. As discussed above, improvement of differentiation and purifica-
tion protocols looks likely to yield more homogenous populations of more 
mature cardiomyocytes in the future. Methodologically, measurement of Ca2+ 
sparks would have been useful to quantify Ca2+ leak and assess the impact of 
different interventions on Ca2+ leak, strengthening the studies mechanistically. 
3.5 Studies in the zebrafish model 
Findings in the zebrafish heart should be extrapolated to humans very cau-
tiously, especially regarding Ca2+ cycling, as some of the the ion channel prop-
erties are different (Zhang et al. 2011). Interesting findings should be studied 
further in mammalian models and e.g. human cell models such as iPSC –
derived cells.  
3.6 Comparison of models 
Electrophysiological and Ca2+ handling characteristics of the different models 
highlighting their weaknesses and differences are provided in tables 4 – 6. On 
several occasions, the results of different studies are contradictory. For com-
parison, characteristics of human adult ventricular myocytes are listed in table 
7.  
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. Electrophysiological characteristics of HEK 293 cells 
AP amplitude (mV) No 
APD90 (ms) No 
Ca2+ signaling Endogenous mediators of store-operated Ca2+ entry > may affect Ca2+ 
signaling (Babnigg et al. 2000) 
Calsequestrin Absent (Itzhaki et al. 2011b) 
dV/dt max (V/s) No 
EC-coupling No 
Funny current Unknown 
Junctin and triadin Unknown 
K+ channels /  
currents 
Some results contradictory. Outward-rectifying delayed K+ current, no Ito 
(Yu et al. 1998). Delayed rectifying K+ current and Ito present (Jiang et al. 
2002a). Voltage-gated and calcium-activated K+ channel proteins pre-
sent (Thomas et al. 2005) 
L-type Ca2+  
channels / current 
Channel absent (Itzhaki et al. 2011b) 
Morphology Pyramidal or rhombic, small hair-like filopodia at membrane periphery 
Na+ channels / 
current 
Channel subunits present (Thomas et al. 2005) 
NCX Absent (Cross et al. 2012) 
Phospholamban Absent (Itzhaki et al. 2011b) 
Resting membrane  
potential (mV) 
-20 – -40 (Thomas et al. 2005)(Thomas 2005) 
RyR2 Absent (Itzhaki et al. 2011b) 
SERCA2a Absent (Itzhaki et al. 2011b) 
SR ER 
T-tubules Absent 
T-type Ca2+  
channels / current 
Unknown 
Summary Useful as a plasma membrane enclosed "test tube" to express 
and study recombinant proteins in relative isolation 
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Table 5. Electrophysiological characteristics of human iPSC ventricular cardiomyo-
cytes 
AP amplitude (mV) 90 – 120 (Zhang et al. 2009a, Moretti et al. 2010, Itzhaki et al. 2011a, 
Ma et al. 2011, Doss et al. 2012, Itzhaki et al. 2012, Kujala et al. 2012, 
Lahti et al. 2012, Novak et al. 2012) 
APD90 (ms) 310 – 500 (Zhang et al. 2009a, Moretti et al. 2010, Itzhaki et al. 2011a, 
Ma et al. 2011, Itzhaki et al. 2012, Kujala et al. 2012, Lahti et al. 
2012)(Doss et al. 2012) 
Ca2+ signaling Large IP3 sensitive Ca2+ stores (Itzhaki et al. 2011b) 
Calsequestrin Some results contradictory. Absent (not there to buffer SR Ca2+), but 
calreticulin is expressed (Li et al. 2013b). Present (Itzhaki et al. 2011b, 
Lee et al. 2011). CASQ2 mRNA levels low compared to levels in adult 
heart, but protein levels similar (Jung et al. 2012). CASQ2 mRNA 
(Germanguz et al. 2011) and also protein present (Novak et al. 2012) 
dV/dt max (V/s) 5 – 40 (Zhang et al. 2009a, Moretti et al. 2010, Itzhaki et al. 2011a, Ma 
et al. 2011, Doss et al. 2012, Itzhaki et al. 2012, Lahti et al. 2012, Novak 
et al. 2012) 
EC-coupling Poor EC-coupling due to lack of T-tubules (Lee et al. 2011) 
Funny current Higher funny current density than in adult CMs* > may promote spon-
taneous beating  (Hoekstra et al. 2012) 
Junctin and triadin Some results contradictory. Absent (not there to facilitate RyR2 func-
tion) (Li et al. 2013b). Present less than in hESC d-CMs* (Lee et al. 2011). 
mRNA levels high compared to levels in adult heart, but protein levels 
similar (Jung et al. 2012). Junctin mRNA, triadin mRNA and protein 
present (Novak et al. 2012) 
K+ channels /  
currents 
Large variation in peak currents of various K+ channels. IKr density similar 
to adult CMs*, IKs density may be higher than in adult CMs*, peak IK1 
one fourth of that in adult CMs* (Ma et al. 2011). Resting membrane 
potential less negative than in adult CMs*, may contribute to spontane-
ous beating. IK1 density increases and spontaneous activity decreases as 
cells mature (Hoekstra et al. 2012). IKr, Ito, IKs: channel subunit mRNA 
levels high, IK1: channel subunit mRNA levels variable compared to adult 
heart levels (Jung et al. 2012). Very small IK1, robust IKr (Doss et al. 2012), 
channel subunit mRNA present (Di Pasquale et al. 2013) 
L-type Ca2+  
channels / current 
Peak current similar to adult CMs*, but highly variable in both groups 
(Hoekstra et al. 2012). Channel subunit mRNA levels similar, but variable 
compared to adult heart levels (Jung et al. 2012). Channel subunit 
mRNA present (Kujala et al. 2012, Di Pasquale et al. 2013) 
Morphology Multiangular, disorganized sarcomeres (Dick et al. 2010). Small cell size 
(Knollmann 2013) 
Na+ channels / 
current 
Similar to adult CMs*, but peak current data for comparison lacking – 
Lower dV/dt max due to lower functional availability of channels be-
cause of higher resting membrane potential (Hoekstra et al. 2012). INa: 
channel subunit mRNA levels similar to adult heart levels (Jung et al. 
2012), Channel subunit mRNA present (Di Pasquale et al. 2013) 
NCX Protein expression shown (less than in hESC d-CMs**), but function not 
studied (Lee et al. 2011). INCX: channel subunit mRNA levels similar com-
pared to adult heart levels (Jung et al. 2012). Peak INCX 2-3 pA/pF, similar 
function as in adult mammalian CMs* (Zhang et al. 2013a). Channel 
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subunit mRNA present (Kujala et al. 2012, Novak et al. 2012) 
Phospholamban Some results contradictory. Absent (Li et al. 2013b). Present (Itzhaki et 
al. 2011b). mRNA levels high compared to levels in adult heart, but 
protein levels similar (Jung et al. 2012). mRNA present (Kujala et al. 
2012) 
Resting membrane  
potential (mV) 
-60 – -80 (Zhang et al. 2009a, Moretti et al. 2010, Itzhaki et al. 2011a, 
Ma et al. 2011, Doss et al. 2012, Itzhaki et al. 2012, Kujala et al. 2012, 
Lahti et al. 2012, Novak et al. 2012) 
RyR2 Present (Itzhaki et al. 2011b). Lower expression than in hESC d-CMs** 
(Lee et al. 2011, Li et al. 2013b). mRNA levels low compared to levels in 
adult heart, but protein levels similar (Jung et al. 2012). mRNA (Kujala et 
al. 2012, Novak et al. 2012) and protein present (Germanguz et al. 2011, 
Itzhaki et al. 2012, Di Pasquale et al. 2013) 
SERCA2a Present (Itzhaki et al. 2011b). Lower expression than in hESC d-CMs** 
(Lee et al. 2011, Li et al. 2013b). mRNA and protein levels similar to 
levels in adult heart (Jung et al. 2012). mRNA present (Kujala et al. 2012, 
Novak et al. 2012) 
SR Immature (Lee et al. 2011) 
T-tubules Immature ultrastructure, no T-tubules (Novak et al. 2012, Li et al. 
2013b) 
T-type Ca2+  
channels / current 
No functional presence (Ma et al. 2011) 
Summary Resemble neonatal cardiomyocytes with small cell size, lack of 
T-tubules, and immature EC-coupling. However, slow matura-
tion does occur (Lundy et al. 2013) 
*CM = cardiomyocyte, **hESC d-CMs = human embryonic stem cell -derived cardiomyocyte. 
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Table . Electrophysiological characteristics of adult zebrafish ventricular cardiomy-
ocytes 
AP amplitude (mV) 99 (Nemtsas et al. 2010) 
APD90 (ms) 150 (Brette et al. 2008), 132 (Nemtsas et al. 2010), 275 in 2 dpf embryos 
at RT* (Jou et al. 2010) 
Ca2+ signaling Sarcolemmal Ca2+ currents, including ICa,T, are more robust than in hu-
mans (Nemtsas et al. 2010) 
Calsequestrin Unknown 
dV/dt max (V/s) 92 (Nemtsas et al. 2010), 6 in 2 dpf embryos at RT* (Jou et al. 2010) 
EC-coupling ICa,L important, but SR less important to EC-coupling (Zhang et al. 2011) 
Funny current Present, but much less than in atria (Warren et al. 2001), present also in 
embryos (Baker et al. 1997) 
Junctin and triadin Unknown 
K+ channels /  
currents 
IKr present, IK1 robustly present, IKs Absent, Ito Absent (Nemtsas et al. 
2010). In embryos IKr present (Baker et al. 1997). IKr and IKs present (Tsai 
et al. 2011)  
L-type Ca2+  
channels / current 
Fivefold larger current density than in human CMs**. Ca2+ dependent 
inactivation similar to that in mammals (Zhang et al. 2011). Current 
density similar to that in mammals (Brette et al. 2008). Robust presence 
(Nemtsas et al. 2010), also in embryos (Baker et al. 1997) 
Morphology Rod-shaped, sarcomeres present (Brette et al. 2008). Striated, but 
smaller than mammalian CMs** (Nemtsas et al. 2010) 
Na+ channels / 
current 
Current density 4 times smaller than in mammals (Brette et al. 2008) 
present (Nemtsas et al. 2010) also in embryos (Baker et al. 1997) 
NCX Contributes to membrane potential and contraction at positive mem-
brane potentials (Zhang et al. 2011) 
Phospholamban Present (Little et al. 2013) 
Resting membrane  
potential (mV) 
-72 (Nemtsas et al. 2010), -68 in 2 dpf embryos at RT* (Jou et al. 2010) 
RyR2 Present as the most highly expressed RyR isoform (Darbandi et al. 2009) 
SERCA2a Present (Little et al. 2013) 
SR SR Ca2+ release contributes to contraction less than in mammals (Zhang 
et al. 2011), also in embryos (Xie et al. 2008b) 
T-tubules Absent (Brette et al. 2008). But smaller cell size allows rapid Ca2+ wave 
propagation 
T-type Ca2+  
channels /  
current 
Robust presence, suggesting an immature phenotype compared to 
mammalian CMs** (Nemtsas et al. 2010), also in embryos (Baker et al. 
1997). Essential for EC-coupling in embryos (Xie et al. 2008b) 
Summary Small cells that lack T-tubules, sarcolemmal currents are more 
important for contractile function than in mammals, SR of less 
importance for EC-coupling. Thus Ca2+ aftertransients and DADs 
are less likely to occur 
*RT = room temperature, **CM = cardiomyocyte. 
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Table 7. Electrophysiological characteristics of human adult ventricular cardiomyo-
cytes 
AP amplitude (mV) 100 – 110 (Drouin et al. 1998, Magyar et al. 2000, Nemtsas et al. 2010) 
APD90 (ms) 210 – 350 (Drouin et al. 1998, Magyar et al. 2000, Nemtsas et al. 2010) 
Ca2+ signaling Rapid and synchronous 
Calsequestrin Present (Zhang et al. 1997) 
dV/dt max (V/s) 180 – 230 (Drouin et al. 1998, Magyar et al. 2000, Nemtsas et al. 2010) 
EC-coupling Essential contribution of SR (Bers 2002) 
Funny current During heart failure (Hoppe et al. 1998) 
Junctin and triadin Present (Zhang et al. 1997) 
K+ channels /  
currents 
Peak Ito 5-16 pA/pF (Näbauer et al. 1996). Peak IK1 3.6 pA/pF (Magyar et 
al. 2000). Peak IKr 0.30 pA/pF (Iost et al. 1998, Magyar et al. 2000). Peak 
IKs 0.20 pA/pF (Virág et al. 2001). Ito and IK1 decreased in heart failure 
(Beuckelmann et al. 1993) 
L-type Ca2+  
Channels /  
current 
Peak current -10 pA/pF (Magyar et al. 2000) 
Morphology Rod-shaped, sarcomeres present 
Na+ channels / 
current 
Robust, as indicated by high dV/dt max. 
NCX Expression increased in heart failure (Hasenfuss et al. 1999) 
Phospholamban Inhibitory effect on SERCA2a increased in heart failure (Frank et al. 
2000) 
Resting membrane  
potential (mV) 
-80 – -90 (Drouin et al. 1998, Magyar et al. 2000, Nemtsas et al. 2010) 
RyR2 Present (Zhang et al. 1997) 
SERCA2a Expression decreased in heart failure (Hasenfuss et al. 1994, Hasenfuss 
et al. 2002) 
SR Essential for EC-coupling (Bers 2002) 
T-tubules Extensive 
T-type Ca2+  
channels / current 
Present under pathological conditions (hypertrophy, heart failure) (Ono 
et al. 2010) 
Summary Mature cardiomyocytes with extensive T-tubules and robust 
EC-coupling, where SR Ca2+ plays an essential role 
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 Conclusions  
The research works included in this thesis were designed as translational stud-
ies, aimed at tackling clinically relevant problems in the lab. Our goal was to 
improve understanding and eventually take this knowledge back to the clinic 
in order to help those, for whom this work is done for in the first place, the 
patients.  
 
Studies I-III investigated CPVT. MAP recordings in the right ventricles dis-
played afterdepolarizations and concomitant U-waves were observed in the 
ECG. These afterdepolarizations 
	
  -agonist stimulation, and 
occasionally triggered APs and ventricular extrasystoles. Cell studies revealed 
an increased propensity to spontaneous SR Ca2+ release by the mutant RyR2 
channels. More detailed studies of mutant RyR2s in iPSC-derived cardiomyo-
cytes showed increased and irregular spontaneous Ca2+ 

	
 	  -
agonist stimulation resulted in decreased SR Ca2+ and increased cytosolic Ca2+ 
concentrations. Interestingly, in addition to DADs, mutant cells also showed 
occasional EADs. Based on the observed variability of Ca2+ cycling in the 
mutant cells, the CPVT patients’ clinical ECG and MAP recordings were ex-
amined for corresponding phenomena. Increased non-alternating variability of 
repolarization was found in the ECG recordings, recapitulating the cell-level 
findings.  
 
Cellular and in vivo AP recordings revealed prolonged depolarization upo-
agonist stimulation in CPVT. Older CPVT patient showed notably reduced R-
spike upslope velocity on 24h ECG recordings. These findings suggest that 
progressively reduced conduction velocity may contribute to an arrhythmic 
substrate in these patients.  
 
The novel iPSC technology is a promising tool for mechanistic studies of ar-
rhythmic disorders. The discovered ECG changes in CPVT patients raise ques-
tions that should be addressed in further studies. Do increased variability of the 
QT interval and prolonged depolarization have value in arrhythmia risk predic-
tion? Can they guide pharmacologic therapy? Or help in choosing the optimal 
treatment strategy (drugs, ICD, sympathetic denervation)? These questions are 
relevant not only for CPVT patients, but all patients at risk of ventricular ar-
rhythmias. 
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Study IV investigated cardiac function in a zebrafish model of polycystic kid-
ney disease. These fish showed signs of heart failure, including reduced cardi-
ac output, edema, and arrhythmias. Detailed studies on excised whole hearts 
showed markedly impaired Ca2+ cycling, indicating that PC2 is necessary for 
maintaining normal Ca2+ handling and cardiac function. Importantly, a data-
base search found that the prevalence of IDCM is high among ADPKD pa-
tients, especially those with PKD2 mutations.  
 
These findings suggest impaired Ca2+ cycling as an essential mechanism of 
cardiac dysfunction in these patients. Furthermore, they encourage future stud-
ies to investigate the mechanism of the association between ADPKD and 
IDCM in more detail. It remains unclear whether screening for early signs of 
cardiac dysfunction in ADPKD patients would result in better cardiac out-
comes. Additionally, the zebrafish proved an attractive model organism for 
studies on cardiac physiology. Its booming popularity in biomedical research 
is likely to continue. 
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Models 
I believe efforts to develop stem cell technologies should continue. The field is 
developing rapidly, and new promising methodologies are introduced fre-
quently (Obokata et al. 2014). The potential benefits are huge. Identification of 
genotype-phenotype correlations and disease mechanisms will progress in 
vitro. On the other hand, physiological experiments will allow scientists to 
optimize treatment in a patient-specific manner, even before possessing de-
tailed knowledge of the complex interplay of modifying genetic factors in that 
individual. This is crucial because a disease such as CPVT may arise from 
hundreds of different mutations, and optimal therapy is likely to be mutation-, 
and even individual patient-, dependent. Additional applications of stem cell 
technologies include toxicology screening, and further down the line, the po-
tential for cell therapy to mend hearts following devastating injuries, such as 
myocardial infarction. 
I think that also zebrafish can be a valuable model organism in high through-
put drug discovery, toxicological studies, and as a first-line in vivo model for 
physiological studies involving drugs, genes, or other molecules of interest. 
When its limits are kept in mind, it can also provide meaningful mechanistic 
insights. 
 
CPVT and other arrhythmias 
Although studying molecular and cell-level mechanisms related to arrhythmias 
is important and stem cell-derived cardiomyocytes open exciting possibilities 
to do this, clinical cardiac electrophysiology will remain the cornerstone. Ar-
rhythmias are complex phenomena, which need to be studied and understood 
at the organ and organism levels. Arrhythmia risk prediction and treatment 
have a long way to improve. As prevention is the best treatment, effort needs 
to be put on risk stratification to learn whom to treat and how, to prevent ad-
verse outcomes. Once we know what signs of risk to look for, I’m confident 
the technology will be there to enable the timely detection of these red flags. 
The focus need to be on ventricular tachyarrhythmias, which remain incom-
pletely understood, especially polymorphic VT in a structurally healthy heart 
(Josephson 2007). Regarding risk stratification and treatment of CPVT, what 
is needed now is a shift from studies on animal models to randomized prospec-
tive placebo controlled clinical trials, which due to the rarity of the condition 
will require a concerted international multi-center approach. If well designed 
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and implemented, such studies will teach us the signs of danger to look for, 
and the usefulness of different therapies. 
 
Technology will change the game 
I envision that the development of portable monitoring devices and applica-
tions, such as simple ECG recordings taken by devices like smart phones, will 
allow follow-up of selected high risk patients and reduce the frequency of 
physical visits to the clinic. ECG readouts sent to the treating physician, per-
haps among other parameters containing data on variability of repolarization 
and alternans, may allow interventions such as changes in pharmacotherapy to 
be taken as preventive measures before adverse events would occur. This ap-
plies not just to patients with inherited arrhythmias, but to all patients at high 
risk of SCD, and even more broadly when readings on weight changes, blood 
glucose, blood pressure etc. are included. 
 
ADPKD 
Studies on the mechanisms of cardiac dysfunction in ADPKD need to take the 
logical next step from zebrafish to mammalian models, as is currently happen-
ing. Once this relationship is understood in more detail, studies on human 
ADPKD patients will hopefully bring benefits in the form of reduced cardiac 
morbidity and mortality to the millions of ADPKD patients world-wide. 
 
It is therefore my humble hope that opportunities are given for translational 
cardiac research and training that will deepen our understanding and most 
importantly, eventually benefit the patients.  
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